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ABSTRACT 
Ocular neovascular diseases, including age related macular degeneration and diabetic 
retinopathy are major causes for blindness in the western world. The pathogenesis of these 
diseases remains partly unclear and currently there is no permanent cure for these diseases. In 
this study, we attempted to clarify the factors involved in the pathogenesis of diabetic 
retinopathy in type 1 and type 2 diabetes. We also experimentally evaluated the effects of 
overexpression of vascular endothelial growth factors (VEGF) -A and –D in the rabbit eye with 
adenovirus and baculovirus vectors. Finally, ocular phenotype of IGF-II/LDLR–/–ApoB100/100 
mouse was studied in order to develop a new animal model for age related eye diseases. 
   Diabetic retinopathy in type 1 and type 2 diabetes showed a different pattern of growth factor 
expression, which may explain the differences seen in these states. In diabetic patients, in 
addition to VEGF-A also other growth factors, particularly angiopoietin 2 were abundantly 
present. VEGF-D seemed to be important especially in type 2 diabetic retinopathy.  
VEGF-A plays a major role in the pathogenesis of ocular neovascularization. Intravitreal 
injection of adenoviral VEGF-A165 into the rabbit eye led to breakdown of the blood-retina 
barrier and ultimately neovessel formation. Furthermore, blocking the action of VEGF-A165 
prevented the progression of the angiogenic process. Intravitreal VEGF-D∆N∆C in our 
experimental series with rabbits led to a similar breakdown of the blood retina barrier as VEGF-
A165 and increased permeability but it was not capable to induce neovessel formation alone.  
   Administration of the therapeutic agent to the retina and choroidea can be difficult due to the 
tight barriers in the eye. Multiple injections into the eye may damage ocular structures and the 
risk of complications including endophthalmitis, cataract and haemorrhages increases. The 
optimal method for the delivery of therapeutic agents to the retina and choroidea has not yet 
been developed. Gene therapy offers an alternative in which the therapeutic protein or proteins 
are induced in the target tissue with a single injection for a prolonged time period. Eye is an 
ideal target for gene therapy because of its small size and tissue boundaries that prevent leakage 
of the therapeutic material to other tissues and systemic circulation. Viruses are widely used as 
vectors in gene transfer. In this study, intravitreal injection of adenovirus vector into the rabbit 
eye was efficient in delivering genes to the ganglion cell layer and inner retina.  Baculoviruses 
showed transduction in the retinal pigment epithelium (RPE) and the photoreceptor layer even 
after the intravitreal injection into the rabbit eye. However, both vectors initiated an immune 
response in the target tissue, which limited the expression of the transducted gene to few weeks.  
   Diabetic IGF-II/LDLR–/–ApoB100/100 mice had moderately increased plasma glucose levels 
simulating early diabetes treated with diet therapy in humans.  Aging transgenic mice showed 
changes especially in their retinal structures. Neovascularization was not seen in the retina. 
Instead, photoreceptor atrophy and dysregularities of normal retinal cell layers were found 
throughout the retina. This model might be useful for the evaluation of early diabetic changes 
and retinal degeneration. 
 
National Library of Medicine Classification: WW 270, WW 245, WK 835 
Medical Subject Headings: Adenoviridae; Angiopoietins; Baculoviridae; Blood-Retinal Barrier; Choroidal 
Neovascularization; Diabetic Retinopathy; Disease Models, Animal; Eye/ blood supply; Gene Therapy; Gene Transfer 
Techniques; Neovascularization, Pathologic/ etiology; Retinal Degeneration; Retinal Neovascularization; Vascular 
Endothelial Growth Factor A; Vascular Endothelial Growth Factor D; Vascular Endothelial Growth Factors 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
”What was that?”, asked 
Moomintroll, for a discovery 
(next to Mysterious Paths, 
Bathing, and Secrets) was what 
he liked most of all. 
                    Tove Jansson 
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1 INTRODUCTION 
 
The human eye is a complex organ composed 
of many sections important to normal visual 
acuity. The cornea, lens, vitreous and outer 
retina are unique avascular structures 
allowing light to enter the eye. The light rays 
focused by the cornea and lens form an image 
to the retina, the light-sensing portion of the 
eye. The photoreceptor cells in the retina 
convert the image into an electrical signal 
that travels down the optic nerve to the brain 
(Figure 1).  
 
 
 
 
 
 
 
Figure 1. Normal anatomy of the eye. Image 
Source: National Eye Institute, National 
Institutes of Health.                                   
   Optical transparency of the eye is needed 
for normal visual function. On the other hand, 
the adult retina is a neural tissue with high 
metabolism and the highest oxygen 
consumption per unit weight of all human 
tissues. Therefore, the choroid, the most 
vascular portion of the eye also nourishing 
the retina, has one of the highest blood flow 
rates in the body, 800-1000 ml/100g 
tissue/min (Alm, 1992). In healthy adults this 
delicate ocular vascular system is maintained 
and controlled by the balance between the 
angiogenic factors and angiogenic inhibitors 
(Cao, 2001; Folkman and Ingber, 1992; Gao 
and Ma, 2002; Ma et al., 2005). 
Angiogenesis, or neovascularization, refers to 
the development of new vessels from 
preexisting vasculature. Most neovascular 
diseases in the eye begin with a shift of the 
balance between angiogenic and 
antiangiogenic factors towards angiogenesis. 
This phenomenon is called the angiogenic 
switch. The angiogenic switch occurs during 
neoplastic processes and various ocular 
diseases, including retinal and choroideal 
angiogenesis. Retinal and choroideal 
neovascularization leads to oedema, 
haemorrhages and fibrosis, causing visual 
impairment and blindness.      
   Diabetic retinopathy and age related 
macular degeneration (AMD) are the leading 
causes for visual impairment in developed 
countries (Table 1). Diabetes mellitus (DM) 
affects over 170 million people worldwide 
and the estimated amount of patients in the 
year 2030 is 366 million. The prevalence of 
diabetes is increasing particularly in low- and 
middle-income countries and in the working 
age population (WHO, 2005).  75% of both 
type 1 and type 2 diabetics will have diabetic 
retinopathy after 20 years of disease 
(Resnikoff et al., 2004).                         
   The incidence, prevalence, and progression 
of AMD increase with advancing age and 
will rise as the population of older than 65 
years increases (Mitchell et al., 2002a). 
Worldwide estimates indicate that the amount 
of AMD patients will double by the year 
2020 (The Eye Diseases Prevalence Research 
Group, 2004). The prevalence of early signs 
of AMD is 18% in the population aged 65 to 
74 years and 30% in the population older than 
74 years (Klein et al., 1992). In a combined 
analysis of population-based eye disease 
prevalence data, AMD was present in 0.2% 
of the population aged 55 to 64 years, rising 
to 13% of the population older than 85 years 
(Smith et al., 2001).  About 900 persons are 
visually impaired due to AMD in Finland 
each year (Finnish Federation of the Visually 
Impaired, 2007). 
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Table 1. Statistics of visual impairment in 
developed countries and the world. 
 
 
Region Western 
countries 
World 
No. of blind people 
(millions) 
2.02 36.86 
Prevalence of blindness, 
% 
0.23 0.57 
No. of blind 
people 
(millions) by 
age (years) 
<15 0.05 1.37 
15-49 0.39 5.18 
>50 1.59 30.31 
No. of people with low 
vision (millions) 
11.35 124.25 
Prevalence of low 
vision, % 
1.23 2.00 
No. of visually 
impaired (millions) 
13.37 161.12 
AMD as a cause of  
blindness, % 
50.00 8.70 
Diabetic retinopathy as 
a cause of blindness,  % 
17.00 4.80 
Modified from WHO global data on visual 
impairment in the year 2002 (Resnikoff et al., 
2004).  Sample of western countries include 
Australia, Denmark, Finland, Iceland, 
Ireland, Italy, Netherlands, UK and USA. 
 
In multiple studies, vascular endothelial 
growth factor (VEGF) has been shown to be 
the most important factor in ocular 
angiogenesis (Adamis et al., 1994; Aiello et 
al., 1994; Kvanta et al., 1996).  Recently 
discovered anti-VEGF treatments have 
revolutionized the therapy of neovascular 
diseases in the eye. These agents have shown 
not just to stop the angiogenic process and 
maintain visual acuity but also improve 
vision in a great proportion of patients at least 
during the two year follow-up (Brown et al., 
2009). However, there are also problems with 
these agents and their delivery regimens and 
new therapeutic strategies are needed.  
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2 REVIEW OF THE LITERATURE  
2.1 DIABETIC RETINOPATHY 
2.1.1 Clinical signs 
Diabetic retinopathy begins as mild, 
nonproliferative abnormalities and progresses 
to moderate and severe nonproliferative 
diabetic retinopathy (Figure 3A) and 
proliferative diabetic retinopathy (Figure 3B). 
Macular edema can develop at any time in 
the progression of diabetic retinopathy 
(Ciulla et al., 2003). Clinical features of 
nonproliferative diabetic retinopathy include 
microaneurysms, intraretinal hemorrhages, 
soft and hard exudates, venous tortuosity or 
beading and intraretinal microvascular 
abnormalities (IRMA) (Davis, 1992). 
Microaneurysms, focal dilations of retinal 
capillaries, are early signs of diabetic 
retinopathy. Hypoxia caused by capillary 
dysregulation provoke nerve fibre layer 
infarctions creating soft exudates, which are 
visualized as gray or white lesions and are the 
result of stasis of axoplasmic flow. Growth 
factors expressed due to hypoxia cause 
induction of fenestrations in the vascular 
endothelium and dissolution of tight junctions 
leading to accumulations of intraretinal 
plasma proteins and hard exudates. Increased 
venous tortuosity and beading is caused by 
dysregulation of the capillaries.  Prolonged 
occlusion of capillaries causes hypoxia, 
which leads to the development of IRMA, 
additional routes for blood through arteries to 
veins.  
   Diabetic retinopathy can be divided into 
stages depending on the severity of the 
disease. Microaneurysms in the retina refer to 
mild nonproliferative diabetic retinopathy. In 
moderate nonproliferative diabetic 
retinopathy there are more changes than 
microaneurysms including soft and hard 
exudates. Severe nonproliferative diabetic 
retinopathy is defined as more than 20 
intraretinal hemorrhages/microaneurysms in 
each of four quadrants, definite venous 
beading in at least two quadrants or 
prominent IRMA with no signs of 
proliferative diabetic retinopathy in any 
quadrant. Proliferative disease is diagnosed in 
the case of neovascularization or preretinal or 
vitreous hemorrhage in the eye. New vessels 
traverse the internal limiting membrane and 
grow into the vitreous. Neovessels are fragile 
and tend to bleed causing vitreous 
hemorrhages. Fibrous scar formation can 
result with accompanying tractional retinal 
detachment, leading to sudden blindness if 
left untreated (Figure 2).  
 
 
Figure 2. (A) Moderate nonproliferative 
diabetic retinopathy with hard exudates (large 
arrows), soft exudates (small arrows) and 
microaneurysms (arrowheads). (B) 
Proliferative diabetic retinopathy and 
neovascularization in the optic disc.   
    
A 
B 
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   The foveal region is especially susceptible 
to hypoxia because of the lack of retinal 
vessels in this region. Diabetic maculopathy 
is characterized by an increase in vascular 
permeability, which results from a 
breakdown of the inner blood retinal barrier 
and leads to leakage of plasma component 
like proteins and lipids to the intaretinal 
space. Clinically significant macular oedema 
occurs if there is thickening of the retina 
involving the area within 500 µm of fovea, if 
there are hard exudates within 500 µm of the 
fovea with thickening of the adjacent retina, 
or if there is a zone of retinal thickening one 
disk area or larger in size, any part of which 
is within one disk diameter of the fovea 
(Early Treatment Diabetic Retinopathy Study 
Research Group, 1985). Changes in the 
macular area cause metamorphopsia, 
micropsia, decreased colour vision and 
contrast sensitivity and are the main reasons 
for moderate visual loss in diabetic patients 
(Daley et al., 1987). It is not clear why some 
diabetic patients develop severe macular 
oedema and others suffer from 
neovascularization and proliferative diabetic 
retinopathy.                                                                                                  
2.1.2 Pathophysiology 
Preretinal neovascularization and chronic 
retinal oedema in the macular area are the 
two major causes for visual loss in diabetic 
retinopathy (Fong et al., 1999).  
Hyperglycaemia induces alterations in the 
pericytes and vascular endothelial cells (EC) 
activating a cascade of signaling pathways 
leading to cellular dysfunction and eventually 
death. Histological lesions in diabetic 
retinopathy include capillary basement 
membrane thickening, EC dysfunction and 
loss, increased deposition of extracellular 
matrix (ECM) components, pericyte loss and 
leucocyte adhesion to the vessel wall (Ansari 
et al., 1998; Koya and King, 1998; Miyamoto 
and Ogura, 1999; Mogensen et al., 1979; 
Paget et al., 1998; Speiser et al., 1968).  
Endothelial dysfunction refers to a 
generalized alteration in EC phenotype and 
function, characterized by an abnormal 
vasodilator response, such as decreased nitric 
oxide or increased production of 
vasoconstrictors, such as endothelin-1 
(Brownlee et al., 1984; Brownlee, 2001; 
Chen et al., 2004; Cukiernik et al., 2003; 
Deng et al., 1999; Dogra et al., 2001; 
Johnstone et al., 1993; Khan and Chakrabarti, 
2003; Khan et al., 2006; McVeigh et al., 
1992; van de Ree et al., 2001).  EC 
dysfunction disrupts autoregulation of retinal 
blood flow, which maintains optimal 
nutrition and oxygenation of the retina in 
different situations of ocular perfusion and 
intraocular pressures.  
   Pericytes are essential in the regulation of 
retinal capillary perfusion, and damage to 
pericytes leads to altered retinal 
hemodynamics (Ciulla et al., 2002). Pericytes 
are responsible for the control of growth and 
survival of ECs, especially under stress 
conditions (Hammes et al., 2002). Damage to 
pericytes may lead to EC migration, growth 
and dysfunction. The absence of pericytes 
correlates with endothelial hyperplasia, 
increase capillary diameter and abnormal 
endothelial morphology (Hellstrom et al., 
2001b). Unlike other organs, there is a high 
number of pericytes in the retinal 
microvasculature (Frank et al., 1990). The 
pericyte-EC ratio is 1:1 in the retina, as 
compared to a ratio of 1:10 in other 
microvasculature beds in the human body 
(Chakravarthy and Gardiner, 1999). Pericytes 
are very sensitive to disruptions of the 
extracellular environment. The level of 
apoptosis is much higher in pericytes than in 
ECs under the same amount of glucose 
concentration fluctuations and diabetic 
conditions (Li et al., 1996; Li et al., 1997).   
   Leukocytes possess large cell volume, high 
cytoplasmic rigidity, a tendency to adhere to 
the vascular endothelium, and a capacity to 
generate toxic superoxide radicals and 
proteolytic enzymes (Miyamoto and Ogura, 
1999).  In diabetes, there is increased retinal 
leukostasis, which affects retinal EC function, 
retinal perfusion, angiogenesis, and vascular 
permeability. In addition, leukocytes in 
diabetic patients are less deformable and may 
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be involved in capillary nonperfusion, EC 
damage, and vascular leakage (Miyamoto and 
Ogura, 1999).  
   Inflammation plays an important role in the 
degeneration of retinal capillaries in diabetic 
patients. The increased expression of many 
inflammatory proteins is regulated at the gene 
transcription level. NFκB is a widely 
expressed inducible transcription factor that 
is an important regulator of many genes 
involved in the inflammatory and immune 
responses, proliferation and apoptosis. NFκB 
is activated in retinal ECs or pericytes 
exposed to elevated glucose concentration 
and in retinas of diabetic rats (Kowluru et al., 
2003; Zheng et al., 2004).  In addition, 
inhibition of NFκB induced proteins inhibits 
diabetes-induced degeneration of retinal 
capillaries. Furthermore, compounds known 
to inhibit NFκB likewise inhibit the 
development of diabetic retinopathy (Kern, 
2007). Increased levels of TNFα, IL-1β, and 
other inflammatory mediators have been 
found in the vitreous of diabetic patients 
(Demircan et al., 2006; Doganay et al., 2002; 
Mysliwiec et al., 2006; Yuuki et al., 2001).  
Activity of caspase-1, the enzyme responsible 
for production of IL-1β, increases in retinas 
of diabetic humans, and correlates with the 
distribution of lesions in the retina (Tang et 
al., 2003).  In addition, deposition of C5b-9, 
the terminal product of complement 
activation, has been observed within retinal 
blood vessels of diabetic humans (Zhang et 
al., 2002).  
   Biochemical abnormalities related to 
diabetes include increased polyol pathway 
flux, which results in elevated levels of 
intracellular sorbitol (Gabbay, 1975). This 
disrupts the osmotic balance and results in 
cellular damage (Gabbay, 1975). In the 
presence of high glucose, carbohydrates 
interact with protein side chains in a 
nonenzymatic fashion to form advanced 
glycation end products (AGEs) (Brownlee et 
al., 1984; Friedman, 1999). AGEs may affect 
such functions as enzyme activity and 
susceptibility of proteins to proteolysis 
(Brownlee et al., 1984).  
   Experimental studies have shown that 
protein kinase C (PKC) activity and levels of 
an activator of PKC, diacylglycerol (DAG), 
are increased in hyperglycemia (Inoguchi et 
al., 1992; Xia et al., 1994). PKC activity is 
also increased after exposure of ECs to 
oxidative stress (Nishikawa et al., 2000; 
Taher et al., 1993). PKC-ß and –δ have been 
identified as the main isoforms of PKC 
activated in vascular tissues in response to 
hyperglycemia (Inoguchi et al., 1992; Koya 
and King, 1998). PKC-ß has been shown to 
have an important role in regulating EC 
permeability (Nagpala et al., 1996). It is also 
an important signaling component for 
angiogenic factors (Xia et al., 1996). The 
PKC-β inhibitor ruboxistaurin has been 
studied in animal and human clinical trials in 
patients with diabetic retinopathy. The trials 
have demonstrated a significant reduction in 
visual loss and need for laser treatment in 
patients with moderate to severe diabetic 
retinopathy over a 3-year period (Aiello et al., 
2006).  
   Production of reactive oxygen species 
(ROS) has also been implicated in the 
development of diabetic complications. 
Diabetes may cause ROS production through 
glucose auto-oxidation and increased flux 
through the polyol pathway (Giugliano et al., 
1996). ROS may activate aldose reductase 
and PKC and increase AGE production and 
DAG formation.  
   Besides vascular changes, chronic 
hyperglycemia also causes damages in retinal 
neural cells and glial cells (Barber, 2003; 
Rungger-Brandle et al., 2000). Retinal 
function is reduced in type 1 diabetics and in 
diabetic animal models (Hancock and Kraft, 
2004; Phipps et al., 2004; Phipps et al., 2007; 
Shirao and Kawasaki, 1998; Simonsen, 
1980).  Electrophysiological changes occur 
before visible retinopathy and can be 
monitored by electroretinogram (ERG) 
(Simonsen, 1980). These changes often 
precede the onset of microvascular lesions 
and predict the worsening of retinopathy 
better than clinical characteristics (Bresnick 
and Palta, 1987; Parisi and Uccioli, 2001).  
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   The optic nerve and visual pathway may 
also be affected as an early manifestation of 
diabetes. A progressive delay of the visual 
evoked potentials of diabetic patients has 
been demonstrated (Anastasi et al., 1985).  
Also nerve fibre layer defects have been 
detected by red-free photography in 20% of 
patients without microaneurysms and in 57% 
of patients with only microaneurysms 
(Chihara et al., 1993). The clinical findings 
on ganglion cell layer (GCL) have been 
confirmed in studies on rodents. Optic nerves 
of spontaneously diabetic rats have 
significantly smaller nerve fibres with 
increased atrophy and dystrophic changes in 
the nerve fibre layer (Sima et al., 1992).  
   Extensive loss of retinal microvasculature 
leads to retinal hypoperfusion, ischemia, and 
subsequent tissue hypoxia. Ocular 
neovascularization is strongly associated with 
retinal ischaemia, and multiple growth factors 
upregulated by hypoxia have been implicated 
in its pathogenesis. The ischaemic retina 
secretes growth factors that stimulate pre-
existing vessels to proliferate. The most 
important of these factors are VEGF, basic 
fibroblast growth factor (bFGF), insulin-like 
growth factor-I (IGF-I), platelet-derived 
growth factor (PDGF) and angiopoietins 
(ANG) (Paques et al., 1997).  Histologic 
studies have demonstrated the presence of 
growth factors and receptors in the preretinal 
membranes and the vitreous humour of 
patients with proliferative diabetic 
retinopathy (Adamis et al., 1994; Aiello et al., 
1994). These factors have also been shown to 
correlate with the neovascular activity.  
   VEGF expression was found to be 
upregulated in rat vessels soon after the 
induction of experimental diabetes suggesting 
that VEGF is implicated in the vascular 
hyperpermeability that occurs early in the 
course of diabetic retinopathy (Vinores et al., 
1997). Furthermore, intravitreal injection of 
VEGF induces vasodilation and 
microaneurysm formation before causing 
neovascularization, in a pattern similar to the 
initial stages of diabetic retinopathy (Miller et 
al., 1997). Several studies have been 
demonstrated an acute increase in serum 
levels of IGF-I preceding the onset of 
proliferative diabetic retinopathy in animal 
models (Grant et al., 1993; Hyer et al., 1988). 
Subsequently, increased IGF-I levels were 
measured in the vitreous of patients with 
proliferative diabetic retinopathy indicating 
that IGF-I may play a role in retinal 
neovascularization (Lee et al., 1994). Several 
in vitro studies have been shown that IGF-I 
can induce almost all steps of the angiogenic 
process including EC proliferation, migration 
and basement membrane degradation (King 
et al., 1985; Nakao-Hayashi et al., 1992; 
Nicosia et al., 1994).  bFGF is stored at high 
concentration within the ECM as an inactive 
complex, and released when ECs dissolve 
ECM via the release of proteases (Bashkin et 
al., 1989; Globus et al., 1989; Presta et al., 
1989). bFGF and hypoxia act synergistically 
to upregulate VEGF in ECs, resulting in 
retinal angiogenesis (Stavri et al., 1995).  
PDGF-B is known to induce a vascularized 
connective tissue stroma formation in many 
angiogenic and proliferative processes 
(Forsberg et al., 1993). Also in retinal 
neovascularization PDGF-B may be involved 
in the formation of fibrovascular retinal 
membranes. ANG-1 has been reported to 
induce sprouting in ECs in vitro, whereas 
ANG-2 appears to play a critical role in 
vascular remodeling (Hayes et al., 1999; 
Koblizek et al., 1998; Kukk et al., 1997; 
Stratmann et al., 1998).  It has been shown 
that ANG-2 is upregulated by hypoxia during 
normal and pathologic angiogenesis (Hackett 
et al., 2000; Oh et al., 1999a).   
 
A 
  
21 
 
 
 
Figure 3. Consequences of hyperglycemia. 
2.2 AGE RELATED MACULAR 
DEGENERATION 
2.2.1 Clinical signs 
AMD can develop to either the dry form with 
RPE and photoreceptor atrophy, or the wet 
form with choroideal neovascularization 
(CNV). In the dry AMD, RPE and therefore 
also photoreceptors in the macular area 
gradually disappear and finally large scars of 
retinal atrofy develop. Geographic atrophy 
leads to gradual progression of visual loss, 
most likely because photoreceptors overlying 
areas of RPE atrophy are metabolically 
dependent on RPE cells (Ambati et al., 
2003). Marked apoptosis of the outer nuclear 
layer (ONL) and the inner nuclear layer 
(INL) of the retina is found near areas of RPE 
atrophy (Dunaief et al., 2002).  The wet 
AMD is responsible for 90% of cases of 
severe visual loss in AMD patients (Bressler 
et al., 1988). In the wet AMD, CNV causes 
sub- and intraretinal accumulation of plasma 
and its components and hemorrhages   
(Figure 4). Vision loss occurs through the 
structural and metabolic damages caused by 
exudates and hemorrhages, and the secondary 
cell death and reactive gliosis. 
Metamorphopsia is a common symptom. 
Repeated and untreated leakage of blood, 
serum, and lipid stimulates fibroglial 
organization leading to a disciform scar 
(Ambati et al., 2003). The disciform scar 
represents an end-stage of AMD. It is usually 
vascularized, almost invariably from the 
choroidal circulation but sometimes with 
retinal contribution as well, and can have 
both subretinal and sub-RPE components 
(Green, 1999; Green and Enger, 2005). The 
degree of RPE and photoreceptor 
degeneration is proportional to the diameter 
and thickness of the disciform scar. A tear of 
the RPE can accompany a minority of 
disciform scars. 
   The disease starts with subretinal drusens. 
Drusens are classified morphologically either 
as hard or soft. Hard drusen are yellow-white 
lesions, typically less than 63 µm in diameter, 
appearing as window defects on fluorescine 
angiography (FAG). In the earliest stage, they 
may be visible ophthalmoscopically as semi-
translucent punctate dots in retroillumination. 
Later in the disease, soft drusen, defined as 
being larger than 63 µm in diameter, may 
appear. (Ambati et al., 2003). Soft drusen 
have a tendency to become confluent, and 
multiple drusens are an independent risk 
factor for visual loss from AMD (Macular 
Photocoagulation Study Group, 1997). In 
addition, they can lead to deficits in macular 
function such as color contrast sensitivity and 
central visual field sensitivity (Frennesson et 
al., 1995; Midena et al., 1994; Midena et al., 
1997; Stangos et al., 1995; Sunness et al., 
1988; Tolentino et al., 1994). A prospective 
evaluation of patients with drusen in the 
fellow eyes of unilateral wet AMD suggests 
that the risk of developing CNV in the second 
eye peaks at 4 years, with an increasing 
incidence of geographic atrophy thereafter 
(Sarraf et al., 1999). Immunohistochemical 
analyses have shown several agents, such as 
apolipoproteins B and E, different 
NEOVASCULARIZATION 
GROWTH 
FACTORS 
HYPOXIA 
VASCULAR 
OCCLUSION 
VASCULAR 
CELL DEATH 
EC 
DYSFUNCTION 
BASEMENT 
MEMBRANE 
AGEs POLYOL 
PATHWAY 
DAG-PKC 
PATHWAY 
PERICYTE 
LOSS 
HYPERGLYCAEMIA 
  
22 
 
immunoglobulins, factor X, amyloid P 
component, complement C5 and C5b-9 
terminal complexes, fibrinogen and 
vitronectin to be present in drusen (Anderson 
et al., 2001; Hageman and Mullins, 1999; 
Hageman et al., 1999). These agents suggest 
a role of immunological and inflammatory 
processes in drusen pathogenesis. 
   The diagnosis of AMD is made with FAG 
and ocular coherence tomography (OCT). In 
dry AMD there is no leakage or oedema but 
atrophy in the macula. The earliest signs of 
CNV are subretinal or sub-RPE oedema 
and/or haemorrhages appearing as a greenish 
gray subretinal tissue in ocular examination. 
FAG leakage patterns of CNV are classified 
either as classic or occult. The former refers 
to discrete areas that hyperfluoresce early and 
continue to exhibit progressive leakage with 
increasing intensity and extent during the 
examination. Occult CNV refers either to a 
fibrovascular RPE detachment with irregular 
elevation of the RPE with stippled 
hyperfluorescence and late leakage, or to late 
leakage of undetermined origin. However, 
subretinal blood or lipid exudates may block 
the angiographic hyperfluorescence. In 
addition, CNV may not exhibit fluorescein 
leakage if it has undergone involution or is 
enveloped by RPE proliferation (Ambati et 
al., 2003).  
   In an OCT image classic CNV may appear 
as a highly reflective, fusiform thickening 
between the retina and the hyperreflective 
external band that corresponds to the 
RPE/Bruch's membrane/choroid complex. In 
addition, intraretinal oedema is present. 
Occult CNV can appear as an elevation of the 
RPE or as an irregularity of the external 
hyperreflective band. In geographic atrophy 
associated with the dry form of AMD, soft 
drusen may be identified as elevations of the 
RPE. Furthermore, atrophy is seen as 
thinning of the retina with an increased 
reflectivity of the choroid caused by the lack 
of pigment in the RPE (Hee et al., 1996).  
2.2.2 Pathophysiology 
Vascular risk factors, smoking, age, race, and 
family history have been shown to be the 
most important pathogenetic factors for the 
development of AMD (Age-Related Eye 
Disease Study Research Group, 2000; 
Delcourt et al., 1998; Klein et al., 1998; 
McCarty et al., 2001; Mitchell et al., 2002b; 
Smith et al., 2001). Also excessive exposure 
to light can damage the retina and has been 
implicated in the development of AMD 
(Tomany et al., 2004). Genetic predisposition 
has been demonstrated by familial 
aggregation studies and twin studies. The 
chromosomes most commonly implicated are 
1q25-31 and 10q26. In particular, variants in 
the gene for the complement factor H (CFH) 
and the genes PLEKHA1/LOC387715, 
Factor B (BF) and complement component 2 
(C2) have been implicated as major risk or 
protective factors for the development of 
AMD (Edwards et al., 2005; Gold et al., 
2006; Hageman et al., 2005; Haines et al., 
2005; Jakobsdottir et al., 2005; Rivera et al., 
2005; Seitsonen et al., 2008). 
   An early pathological change in AMD is 
the appearance of basal laminar deposits 
(BlamD) and basal linear deposits (BlinD) 
(Green and Enger, 2005; Green and Key, 
2005). BlamD consist of membrano-granular 
material between the plasma membrane and 
basal lamina of the RPE. BlinD consist of 
vesicular material located in the inner 
collagenous zone of Bruch's membrane. 
Although BlamD persists in areas of 
geographic atrophy, BlinD disappears, which 
is consistent with the fact that BlinD arises 
mostly from the RPE-photoreceptor complex 
(Sarks et al., 1994). BlinD may be more 
specific to AMD than BlamD (Curcio and 
Millican, 1999). Soft drusen can represent 
focal accentuations of BlinD and a localized 
accumulation of BlamD (Bressler et al., 
1994).  
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Figure 4. Wet form of age related macular 
degeneration with oedema, CNV (arrows) 
and haemorrhages (arrowheads). (A)  Fundus 
photograph. (B) FAG image in the 30 sec 
time point.   
 
   The RPE serves a variety of metabolic and 
supportive functions that are of vital 
importance for retinal photoreceptors, 
including maintenance of the blood-retina 
barrier, participation in the visual cycle, and 
phagocytic uptake and degradation of 
constantly shed apical photoreceptor outer 
segments (Strauss, 2005). Furthermore, in 
addition to many other growth factors the 
RPE produces VEGF in vivo under 
physiologic conditions to maintain the 
fenestrated choriocapillaris endothelium (Kim 
et al., 1999). One of the reasons for the RPE 
dysfunction is an age-dependent phagocytic 
and metabolic insufficiency of postmitotic 
RPE cells. Impaired phagocytosis of 
photoreceptor outer segments by the RPE 
leads to a progressive accumulation of 
lipofuscin granules, a diverse group of 
autofluorescent lipid and protein aggregates, 
in the RPE (Kennedy et al., 1995; Sparrow 
and Boulton, 2005; Warburton et al., 2005). 
Lipofuscin accumulation reduces RPE 
phagocytic capacity (Sundelin et al., 1998), 
increases with age and is concentrated in the 
macula (Delori et al., 2001; Wing et al., 
1978). Lipofuscin disrupts RPE function by 
mechanical distortion of cellular architecture 
and potentiating phototoxicity. RPE cells fed 
lipofuscin granules and exposed to short 
wavelength visible light (390–550 nm) 
undergo lipid peroxidation, suffer structural 
disintegrity and ultimately cell death (Davies 
et al., 2001; Rózanowska et al., 1995; Shamsi 
and Boulton 2001).       
   Oxidative stress has a significant role in the 
pathogenesis of AMD (Beatty et al., 2000).  
The phagocytosis of photoreceptor outer 
segments by RPE cells generates oxidative 
stress caused by ROS (Tate et al., 1995).  
H2O2 treatment of RPE cells results in 
marked mitochondrial DNA damage 
(Ballinger et al., 1999). Photoreceptor outer 
segments enriched in polyunsaturated fatty 
acids can undergo lipid peroxidation. In vitro 
studies show that RPE lipofuscin is a 
photoinducible generator of ROS that can 
compromise lysosomal integrity, induce lipid 
peroxidation, reduce phagocytic capacity and 
cause RPE cell death (Boulton et al., 1993; 
Holz et al., 1999; Sundelin et al., 1998). 
Lipofuscin granules are continuously exposed 
to visible light and high oxygen tension, 
which cause ROS production and possibly 
further oxidative damage to the RPE cell 
proteins and lipid membranes (Wassell et al., 
1999; Winkler et al., 1999). In humans, lipid 
peroxidation is greatest in the macula, 
particularly with age (De La Paz and 
Anderson, 1992; Stone et al., 1979; van Kuijk 
and Buck, 1992). Furthermore, AGE products 
occur at sites of oxidant stress with hydroxyl 
radical formation. AGE products occur in soft 
drusen, in BlamD and BlinD, and in the cell 
cytoplasm of RPE associated with CNV 
(Crabb et al., 2002; Ishibashi et al., 1998). 
A 
B 
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   It has been postulated that choroidal 
dendritic cells are activated and recruited by 
injured RPE and oxidized proteins and lipids 
in the Bruch's membrane (Hageman et al., 
2001). The RPE cells respond to dendritic 
cell activation by secreting immune response 
modulators including vitronectin and 
apolipoprotein E (Johnson et al., 2001). 
Activation of choroidal dendritic cells might 
also initiate an autoimmune response to 
retinal or RPE antigens (Hageman et al., 
2001). Antiretinal and anti–RPE antibodies 
have been detected in the serum of patients 
with AMD (Gurne et al., 1991; Niederkorn, 
1990; Penfold et al., 1990). Inflammatory 
cells like multinucleated giant cells and 
leukocytes are involved in the later stages of 
AMD (Killingsworth et al., 1990; Penfold et 
al., 1985; Seregard et al., 1994). 
Macrophages near the Bruch’s membrane 
become more common when BlinD is present 
(Killingsworth et al., 1990). Activated 
macrophages and other inflammatory cells 
secrete enzymes that can damage cells and 
degrade the Bruch’s membrane. By releasing 
cytokines, inflammatory cells might promote 
the growth of CNV into the sub-RPE space 
(Oh et al., 1999b).  
   Wet AMD is characterized by the 
proliferation of CNV. CNV originates from 
the choroid and extends through a defect in 
Bruch's membrane and into a plane between 
BlamD and Bruch's membrane (Green and 
Enger, 2005). CNV can also extend through 
the RPE into the subretinal space. CNV arise 
as capillary-like structures with multiple 
points of origin (Green and Enger, 2005; 
Green and Key, 2005; Schneider et al., 1998). 
CNV can cause serous detachment of the 
RPE or retina, pigment modeling, RPE tears, 
haemorrhages and lipid exudation. 
Morphometric data indicate that the elastic 
lamina of Bruch's membrane in the macula is 
3-6-fold thinner and 2-5-fold less dense 
relative to that in the mid-periphery in 
individuals of all ages rendering the macula 
more susceptible to the ingrowth of CNV 
than peripheral retina (Chong et al., 2005). 
Elastin fiber destruction in the macula could 
also play a role in the initiation of CNV 
because elastin degradation peptides are 
highly angiogenic (Kamisato et al., 1997; 
Nackman et al., 1997). High concentrations 
of VEGF and VEGF receptors are found in 
CNVs, surrounding tissue, and RPE cells 
(Kliffen et al., 1997; Kvanta et al., 1996; 
Lopez et al., 1996). Levels of VEGF are 
increased in cadaver AMD eyes, in the 
vitreous of patients with AMD, and in the 
plasma of patients with AMD (Kliffen et al., 
1997; Lip et al., 2001; Wells et al., 1996). 
ANG-1, ANG-2, and Tie-2 immunoreactivity 
have been found in CNVs from AMD eyes 
(Otani et al., 1999). Cultured RPE cells also 
express ANG-1 and ANG-2 mRNA (Hangai 
et al., 2001).   
 
 
 
 
Figure 5. Consequences of wet AMD. 
 
2.3 OTHER ANGIOPROLIFERATIVE 
DISEASES  
 
The main pathogenesis is comprised of 
neovascularization and upregulation of 
VEGF also in several other diseases in the 
retina. These include retinal angiomatous 
proliferation, retinal telangiectasia, retinal 
vein occlusions and retinopathy of 
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prematurity (ROP). ROP is a disease in 
premature babies characterized by incomplete 
vascularization of the peripheral retina 
leading to retinal neovascularization (Terry, 
1942). Angiogenesis can lead to both normal 
and abnormal vessel formation. In 
experimental oxygen induced retinopathy 
(OIR) model, VEGF levels have been shown 
to rise resulting in neovascularization (Pierce 
et al., 1995; Smith et al., 1994). This finding 
was confirmed with elevated VEGF levels in 
the vitreous of an ROP patient (Young et al., 
1997). However, VEGF is also involved in 
normal vascular embryogenesis of the retina 
(Alon et al., 1995; Ozaki et al., 2000; Pierce 
et al., 1996; Stone et al., 1995). In addition to 
VEGF insulin-like growth factor I (IGF-I) is 
critical for normal retinal vascular 
development. A lack of IGF-I in the early 
neonatal period is associated with the 
proliferative ROP (Hellstrom et al., 2001a).  
Supplementation of IGF in preterm infants 
prior to the development of ROP could 
stimulate normal vessel development and 
prevent ROP. However, in the proliferative 
phase of ROP, IGF-I has been shown to 
stimulate neovascularization independent of 
VEGF levels as well as potentially regulate 
the effects of VEGF (Smith et al., 1999).  
Current therapy consists of monitoring 
oxygen supplementation, aggressive 
screening in children who are at risk of 
having ROP and laser treatment of the retina 
once threshold disease is reached (Palmer et 
al., 2005).  
   Pathological angiogenesis also occurs in 
tissues in the anterior segment of the eye. 
Neovascularization of the iris typically occurs 
within ischemic retinopathies like ischemic 
ocular syndrome and central retinal vein 
occlusion, and can cause loss of vision 
through the associated closure of the irido-
corneal drainage angle, resulting in raised 
intraocular pressure and neovascular 
glaucoma. Neovascularization of the cornea 
can occur in response to a number of 
different insults, including trauma, infection 
or inflammation (Chang et al., 2001).  
2.4 ANGIOGENIC FACTORS 
2.4.1 Vascular endothelial growth factors 
The first and the most potent member of 
VEGF-family, VEGF (also called VEGF-A), 
was first identified in highly vascularized 
tumors in 1983 (Ferrara and Henzel, 1989; 
Senger et al., 1983).  After the discovery of 
VEGF, four other members in the human 
VEGF family have been identified: VEGF-B, 
VEGF-C, VEGF-D, and placental growth 
factor (PlGF) (Achen et al., 1998; Joukov et 
al., 1997b; Maglione et al., 1991; Olofsson et 
al., 1996). In addition to these VEGFs, viral 
VEGF homologs (VEGF-E) and snake 
venom VEGFs (VEGF-F) have been found 
(Ogawa et al., 1998; Yamazaki et al., 2003). 
VEGF is a 46-kDa homodimeric glycoprotein 
with several isoforms including VEGF121, 
VEGF145, VEGF165, VEGF189, and VEGF206 
generated by alternative mRNA splicing from 
the same gene (Ferrara et al., 1991). It is a 
potent angiogenic stimulator, promoting 
proliferation, migration, proteolytic activity 
and capillary tube formation of ECs, thus 
playing a crucial role in both normal and 
pathological angiogenesis (Aiello and Wong, 
2000; Dvorak et al., 1995; Ferrara and 
Henzel, 1989). Heterozygous deletion of the 
VEGF gene results in embryo death between 
days 8.5 and 9.5. The embryos are 
characterized by impaired angiogenesis 
(Carmeliet et al., 1996). VEGF increases 
vascular permeability with an efficacy 5000-
fold higher than that of histamine (Senger et 
al., 1996). Injection of VEGF into the 
vitreous can induce preretinal and iris 
neovascularization (Tolentino et al., 1996; 
Tolentino and Adamis, 1998). In the retina, 
VEGF is produced by multiple cell types, 
including the RPE, pericytes, ECs, Müller 
cells and ganglion cells (Dorey et al., 1996; 
Lu et al., 1999; Pe'er et al., 1995). Among 
them, Müller cells and RPE are believed to be 
the major source of VEGF in the retina, and 
ECs to be the primary target of VEGF (Aiello 
et al., 1994; Dorey et al., 1996; Pierce et al., 
1995). VEGF synthesis is strongly 
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upregulated by hypoxia (Aiello et al., 1995b; 
Marti and Risau, 1998).  
   VEGF levels in the ocular fluid are very 
low in the normal eye (Aiello et al., 1994; 
Ogata et al., 2002). In normal adult monkey 
and mouse eyes, the most abundantly 
expressed isoforms are VEGF121 and 
VEGF165 (Kim et al., 1999). In humans, 
intravitreal levels of VEGF were elevated in 
proliferative diabetic retinopathy (Adamis et 
al., 1994; Aiello et al., 1994). Therapeutic 
laser photocoagulation decreases VEGF 
levels in the vitreous humour by 75% in 
patients with proliferative diabetic 
retinopathy, suggesting that the development 
and regression of retinal neovascularization is 
associated with VEGF levels in the diabetic 
eye (Aiello et al., 1994). In addition, 
significantly elevated VEGF levels in the 
aqueous humor have been reported in 
diabetic patients with macular edema 
(Funatsu et al., 2002).  High levels of VEGF 
are also found in CNV membranes excised 
from patients with AMD and in the vitreous 
humour of a ROP baby (Kvanta et al., 1996; 
Rakic et al., 2003; Young et al., 1997).   
   Different VEGF isoforms may have 
different functions in ocular diseases. 
VEGF165 has been shown to be the most 
important isoform in the blood-retina barrier 
breakdown and pathologic intraocular 
neovascularization (Ferrara et al., 2003). 
VEGF165 is the predominant isoform 
expressed at the time of maximal preretinal 
neovascularization in a neonatal rat model 
(McColm et al., 2004). It is also the primary 
isoform in the retina of diabetic rats (Ishida et 
al., 2003; Usui et al., 2004). Levels of both 
VEGF121 and VEGF165 are increased in 
monkeys after laser-induced retinal vein 
occlusion (Shima et al., 1996). VEGF121 is 
the main isoform expressed in mouse CNV 
membranes, and inhibition of VEGF121 
results in reduction of CNV in mice 
(Akiyama et al., 2005; Rakic et al., 2003).  
   VEGF has also been shown to have 
neuroprotective properties in the retina (Jin et 
al., 2000). Intravitreal VEGF165 and VEGF121 
displayed a protective effect on apoptotic 
retinal cells in a retinal ischemia–reperfusion 
rat model. This protective effect was 
inhibited by blockade of all VEGF isoforms 
but not by blockade of VEGF165 alone (Shima 
et al., 2004). It seems that VEGF isoforms 
may differ in neuroprotection suggesting that 
specific VEGF isoform targeting would be 
beneficial in blocking vessel growth and 
sparing the neuroprotective effects. In 
addition, VEGF acts as a survival factor for 
newly formed blood vessels in the retina and 
also inhibits apoptosis induced by tumor 
necrosis factor (Alon et al., 1995; 
Spyridopoulos et al., 1997). Development of 
the choroideal circulation is dependent on 
VEGF produced by RPE (Yi et al., 1998). 
The RPE expresses VEGF and the ECs of the 
choriocapillaris express VEGFR-2 which 
supports the role for VEGF in the 
maintenance of the adult choriocapillaris 
(Kim et al., 1999). Long-term therapeutic 
neutralization of VEGF may lead to the 
unexpected degeneration of the choroidal 
circulation (Peters et al., 2007).  
   Also other members of the VEGF family 
stimulate neovascularization and excessive 
vascular permeability. PlGF, VEGF-B, 
VEGF-C and VEGF-D are EC mitogens in 
vitro and in vivo, but their role in ocular 
angiogenesis remains unclear (Achen et al., 
1998; Olofsson et al., 1996). VEGF-B does 
not seem to play a role in retinal 
neovascularization, because mice deficient in 
VEGF-B have normal retinal vascular 
development and no difference in hypoxia-
induced retinal neovascularization when 
compared to wild type mice (Reichelt et al., 
2003).  VEGF-C and VEGF-D are produced 
as prepropeptides and further processed to 
biologically fully active forms (Achen et al., 
1998; Joukov et al., 1997a). VEGF-C and 
VEGF-D are involved primarily in 
lymphangiogenesis but also in angiogenesis 
(Cao et al., 1998; Jeltsch et al., 1997; 
Marconcini et al., 1999). VEGF-C and 
VEGF-D have been found in subretinal 
vascular membranes of AMD patients 
implicating a role also in ocular angiogenesis 
(Ikeda et al., 2006). PlGF has also been 
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Figure 6. VEGF family and VEGF receptors.
 
directly implicated in proliferative 
retinopathy (Khaliq et al., 1998).  Knockout 
of PlGF or neutralization with an anti-PlGF 
antibody substantially suppresses retinal 
neovascularization (Carmeliet et al., 2001; 
Luttun et al., 2002).  
 
2.4.2 VEGF Receptors 
VEGF exerts its biological activities through 
multiple receptors; VEGFR-1 (Flt-1), 
VEGFR-2 (Flk-1/KDR) and VEGFR-3 (Flt-
4) which are expressed predominantly in 
ECs, and to a lesser extent on monocytes and 
macrophages (Ferrara et al., 2003; Terman et 
al., 1992).  The binding of VEGF to its 
receptors initiates a signal transduction 
cascade mediating vascular permeability and 
EC proliferation and migration. In addition, 
two co-receptors for VEGF, neuropilin-1 and 
2 (Nrp-1 and Nrp-2) has been described 
(Soker et al., 1998; Soker et al., 2002). 
VEGFR-1 binds VEGF, VEGF-B and PlGF. 
VEGFR-2 binds VEGF and proteolytically 
modified VEGF-C and –D. VEGFR-3 binds 
VEGF-C and -D and mediates 
lymphangiogenesis (Figure 6). The VEGF 
receptors are almost exclusively found on 
ECs. Homozygous VEGFR-1 deletion 
permits EC differentiation, but the vascular 
channels that form are grossly abnormal, and  
 
the animals die in utero (Fong et al., 1995). 
Homozygous deletion of VEGFR-2 leads to 
death of mice between embryonic days 8.5 
and 9.5, with the embryos having no yolk–sac 
blood islands and ECs (Shalaby et al., 1995). 
In the histopathological analysis of a normal 
human retina and choroid, choriocapillaris 
shows an immunohistochemical positive 
reaction with VEGFR-1 and VEFGR-2. 
Furthermore, VEGFR-3 is present in the 
VEGFR-2 positive choriocapillaris 
endothelium that faces the RPE layer 
(Blaauwgeers et al., 1999).  VEGFR-2 is the 
major mediator of mitogenesis of ECs (Gille 
et al., 2001). By activating VEGFR-1, VEGF 
promotes assembly of ECs into tubes. The 
role of VEGFR-1 is context dependent. In 
embryos and some adult tissues, it acts as a 
decoy receptor that modulates angiogenesis 
and in some adult tissues it mediates VEGF 
signaling and is proangiogenic (Fong et al., 
1999; Luttun et al., 2002; Park et al., 1994).  
In the eye, VEGFR-1 is proangiogenic, and 
its inhibition can suppress retinal or 
choroideal neovascularization (Shen et al., 
2006). VEGF also interacts with neuropilins 
(Klagsbrun et al., 2002; Neufeld et al., 2002). 
In early development, Nrp-1 is expressed in 
arteries and Nrp-2 is expressed in veins 
(Herzog et al., 2001). The absence or 
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blockade of either Nrp-1 or -2 suppresses 
ocular neovascularization (Oh et al., 2002; 
Shen et al., 2004). Neuropilins do not have 
kinase domains and must complex with 
VEGF receptors for intracellular signaling to 
occur. Nrp-1 is involved in retinal 
neovascularization in diabetic retinopathy 
and in ischemic animal models (Ishida et al., 
2000; Ishihama et al., 2001). Coexpression of 
VEGFR-2 and Nrp-2 was suggested to 
facilitate fibrovascular proliferation in 
diabetic retinopathy (Ishida et al., 2000).  
2.4.3 PDGFs    
The platelet-derived growth factor (PDGF) 
was one of the first isolated and cloned 
angiogenic growth factors (Saint-Geniez and 
D'Amore, 2004). The PDGF family of growth 
factors is composed of four different 
polypeptide chains. The four PDGF chains 
assemble into disulphide-bonded dimers via 
homo- or heterodimerization, and five 
different dimeric isoforms have been 
described so far; PDGF-AA, PDGF-AB, 
PDGF-BB, PDGF-CC and PDGF-DD 
(Fredriksson et al., 2004; Li et al., 2005). 
PDGF-A and PDGF-B chains were 
discovered more than two decades ago, and 
only recently were PDGF-C and PDGF-D, 
also known as Iris-expressed growth factor, 
chains discovered (Bergsten et al., 2001; 
Heidaran et al., 1991; Hirst et al., 1996; 
LaRochelle et al., 2001; Li et al., 2000; 
Seifert et al., 1989). The overall sequence 
homology among the different growth factor 
domains of the PDGFs is around 25%, while 
PDGF-A and PDGF-B are approximately 
50% identical. Similarly, the growth factor 
domains in PDGF-C and PDGF-D display 
approximately 50% homology (Fredriksson 
et al., 2004). There are two PDGF receptors: 
the PDGF α receptor (PDGFαR) and the 
PDGF ß receptor (PDGFßR). The PDGFαR 
binds both PDGF-A and -B and therefore 
PDGF-AA, -BB, and -AB can all activate 
PDGFαR. PDGFßR binds PDGF-B but not -
A, and therefore PDGF-BB, but not -AA, can 
activate PDGFßR. The action of PDGF-AB is 
more complex, but it appears that at 
physiologically relevant concentrations, 
PDGF-AB can activate PDGFßR only in 
combination with PDGFαR (Seifert et al., 
1993). Unlike PDGF-A and -B, PDGF-C and 
-D are secreted as inactive proteins that are 
activated by proteolytic cleavage, but similar 
to PDGF-A and -B, they signal through 
PDGFαR or PDGFßR (Mori et al., 2002a). In 
the retina PDGFs are generally considered as 
pericyte recruitment and survival factor 
(Hellstrom et al., 2001b; Leveen et al., 1994; 
Lindahl et al., 1997).  PDGF-BB and PDGF-
CC are more potent in stimulating 
angiogenesis than PDGF-AA (Li et al., 2005; 
Risau et al., 1992). Additionally, significantly 
elevated concentrations of PDGF-AB are 
found in the vitreous and preretinal 
membranes of patients with proliferative 
diabetic retinopathy (Freyberger et al., 2000; 
Robbins et al., 1994).  
2.4.4 Angiopoietins 
Angiopoietin-1 (ANG-1) and angiopoietin-2 
(ANG-2) belong to a family of endothelial 
growth factors that function as ligands for the 
endothelial cell-specific receptor tyrosine 
kinase, Tie-2 (Nourhaghighi et al., 2003). 
Also Tie-1 has been identified but there is no 
ligand found for it. ANG-1 and ANG-2 share 
60% amino acid homology (Davis et al., 
1996). Tie-1 and Tie-2 receptors are 
selectively expressed on vascular ECs and are 
required for embryonic vascular development 
(Dumont et al., 1994; Sato et al., 1995). 
Activation of Tie-2 promotes maturation of 
leaky vascular tubes into competent blood 
vessels. Over-expression of ANG-1 in the 
retina significantly reduced VEGF-induced 
retinal vascular permeability, and also 
suppressed the development of retinal 
neovascularization in an OIR model and in 
laser-induced CNV (Nambu et al., 2004). 
ANG-2 acts as an endogenous antagonist of 
the action of ANG-1 by decreasing its 
binding to Tie-2 (Maisonpierre et al., 1997). 
ANG-2 is upregulated by hypoxia and 
angiogenic cytokines including VEGF. In 
addition, it is involved in pathologic 
angiogenesis associated with ischemia in the 
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retina in an animal model and in CNV 
associated with AMD (Mandriota and 
Pepper, 1998; Oh et al., 1999a; Otani et al., 
1999).  Mice deficient in ANG-2 showed 
delayed and incomplete development of the 
superficial vascular bed of the retina, and 
complete absence of the intermediate and 
deep vascular beds, suggesting that ANG-2 is 
a crucial factor in the maturation of retinal 
vasculature (Hackett et al., 2002). In patients 
with ROP, colocalization of Tie-2, VEGF and 
ANG-2, but not ANG-1 was observed in 
fibrovascular membrane, suggesting a 
pathological role of ANG-2 and Tie-2 in 
retinal neovascularization (Umeda et al., 
2003). In OIR mice, ANG-2 expression was 
up-regulated in the retina during the period of 
angiogenesis and reached the peak at the 
maximal angiogenic response (Das et al., 
2003). In addition, ANG-2 has also been 
shown to enhance the sensitivity of retinal 
blood vessels to VEGF (Oshima et al., 2004).   
2.4.5 IGFs 
Insulin-like growth factors (IGF-I and IGF-II) 
are growth-promoting peptides with multiple 
biological effects (LeRoith and Roberts, 
1993). IGF-I was initially identified as a 
circulating factor that appeared to mediate the 
effects of growth hormone (Salmon and 
Daughaday, 1957). IGF exerts its effect on 
ECs via the IGF receptors (IGF-IR and IGF-
IIR) (Miller et al., 1997). Also six well-
characterized IGF binding proteins (IGFBP) 
have been found in circulation and 
extracellular fluids and can inhibit or 
potentiate IGF-I activity (LeRoith and 
Roberts, 1993). IGF-I is known to be present 
in small amounts in normal retina, and IGF-
IRs are found in retinal vascular ECs (Grant 
and Guay, 1991). IGF-I mediates both 
physiological and pathological 
neovascularization by stimulating migration 
and proliferation of retinal ECs and RPE cells 
and tube formation of retinal ECs (Grant et 
al., 1990). In the course of diabetic 
retinopathy, serum IGF-I levels were elevated 
in patients with proliferative disease (Dills et 
al., 1991). Also intravitreal levels of IGF-I 
were found to be elevated during proliferative 
diabetic retinopathy (Grant et al., 1986; 
Meyer-Schwickerath et al., 1993). 
   Normoglycemic transgenic mice 
overexpressing IGF-I in the retina developed 
several vascular alterations characteristic for 
DM including pericyte loss, thickened 
capillary basement membrane, IRMA, 
proliferative changes and retinal detachment 
(Ruberte et al., 2004).  IGF-I have not been 
found to have a causative role in diabetic 
retinopathy but may act as an aggravating 
factor (Miller et al., 1997). In IGF-I knockout 
mice, normal retinal vascular development 
was arrested, despite the presence of VEGF 
(Smith et al., 1999). In a study on premature 
infants, the development of ROP was 
strongly associated with a prolonged period 
of low levels of IGF-I (Hellstrom et al., 
2001a). Infants with higher IGF-I levels 
earlier in life had more normal retinal 
vascular development, and did not have ROP. 
Thus, IGF-I has a critical role in normal 
retinal vascular development suggesting that 
the lack of IGF-I in the early neonatal period 
increases the risk of having ROP (Das and 
McGuire, 2003).  Although the role of IGF-I 
in retinal neovascularization has been studied 
extensively, its role in CNV is still not clear.  
2.4.6 FGFs 
Acidic and basic fibroblast growth factors are 
prototypes of the fibroblast growth factor 
(FGF) family. Basic fibroblast growth factor 
(bFGF) is the best characterized of the FGFs 
(Miller et al., 1997). It belongs to a large 
family of growth factors consisted of over 23 
proteins. bFGF lacks a signal sequence, 
remains cell-associated and is apparently not 
secreted (Miller et al., 1997).  Therefore, the 
origin of its presence in the ECM is not clear. 
bFGF has been localized to the astrocytes of 
the ganglion cell layer, as well as to the cells 
of the inner nuclear layer (Gao and 
Hollyfield, 1992; Kostyk et al., 1994). bFGF 
has a high affinity for heparin which protects 
it from inactivation and degradation 
(Gospodarowicz and Cheng, 1986; Sommer 
and Rifkin, 1989). bFGF has been shown to 
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stimulate EC proliferation and migration. In 
addition, it induces capillary ECs to form 
capillary-like tubes (Mignatti et al., 1989; 
Montesano et al., 1986).   
   The role of FGF in ocular angiogenesis is 
controversial.  In the OIR mouse model, 
FGF-like polypeptides were found to be 
elevated in the retinal tissues during 
neovascularization (Nyberg et al., 1990). 
bFGF injected into the subretinal space in 
rabbits induced subretinal neovascular 
membranes histologically similar to those 
seen in patients with AMD (Kimura et al., 
1999). In an animal model of laser-induced 
subretinal neovascularization, RPE cells 
stained with both aFGF and bFGF after laser 
treatment, indicating the role of these factors 
in choroidal angiogenesis (Zhang et al., 
1993).  Some studies have reported elevated 
levels of bFGF in vitreous humour and retinal 
neovascular membranes in patients with 
proliferative diabetic retinopathy (Frank et 
al., 1996; Hanneken et al., 1991; Sivalingam 
et al., 1990).  However, actively growing 
neovascular membranes show only minimal 
bFGF in the basement membranes of new 
vessels in spite of their capacity to bind 
exogenous bFGF (Hanneken et al., 1991). In 
the retina, overexpression of bFGF could not 
induce neovascularization (Ozaki et al., 
1998).  Transgenic mice deficient in bFGF 
developed the same amount of retinal or 
CNV as the wild-type mice in OIR or laser-
induced subretinal neovascularization 
models, indicating bFGF expression may not 
be necessary for the development of 
choroidal or retinal new vessels (Ozaki et al., 
1998; Tobe et al., 1998b). It has been 
hypothesized that increased retinal expression 
of bFGF is angiogenic only when there is 
accompanied cell injury unmasking control 
mechanisms that sequester bFGF (Yamada et 
al., 2000).   
2.4.7 HIF-1 
Hypoxia inducible factor (HIF)-1 is a 
transcription factor that regulates the 
response to both acute and chronic hypoxia. 
It is the primary hypoxic signaling protein in 
cells for regulating angiogenesis and is able 
to induce the transcription of more than 70 
genes (Semenza, 2004). HIF-1 stimulates the 
transcription of genes whose promoters 
include a hypoxia-response element (HRE) 
(Semenza and Wang, 1992; Tian et al., 1997; 
Wiesener et al., 1998). Products of these 
genes mediate the restoration of tissue 
oxygenation and limit tissue damage. HIF-1 
is a heterodimeric transcription factor that 
typically consists of an oxygen-regulated 
labile 120 kDa HIF-1α subunit and a 
constitutively expressed stable 92 kDa HIF-
1β subunit (Wang et al., 1995). Two other 
HIF molecules, HIF-2α and HIF-3α, have 
also been described (Wiesener et al., 1998).  
Homozygous knockouts of HIF-1α are 
embryonic lethal, whereas HIF-2α knockouts 
have less severe phenotypes but still exhibit 
vascular and respiratory abnormalities as well 
as blindness in mice one month old (Ding et 
al., 2005; Iyer et al., 1998).  Expression of the 
HIF-1α subunit is tightly regulated by the 
cellular oxygen concentration, but HIF-1β is 
oxygen insensitive. HIF-1α increases 
exponentially as oxygen concentration 
declines and determines the level of HIF-1 
activity (Jiang et al., 1996; Semenza et al., 
1996; Wang et al., 1995).  Under normoxic 
conditions, HIF-1α is continuously 
synthesized and degraded proteosomally but 
in exposure to low oxygen tensions, it 
accumulates rapidly and begins to act as a 
transcriptor factor by moving into the nucleus 
and activating an array of genes (Huang et 
al., 1998; Kallio et al., 1999; Salceda and 
Caro, 1997). In developing retina and in OIR 
mouse model HIF-1α levels have shown to be 
significantly increased (Ozaki et al., 1999).  
HIF-1α levels are also high in the nerves of 
diabetic rats (Chavez et al., 2005). HIF-1α 
has been found in neovascular membranes 
from diabetic patients (Abu El-Asrar et al., 
2007). Furthermore, the role of HIF in ROP 
has been implicated in experimental studies 
(Brafman et al., 2004; Morita et al., 2003).  
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2.5 GENE THERAPY 
 
Gene therapy is a promising strategy for the 
treatment of several inherited and acquired 
diseases in the eye. Gene therapy means the 
delivering of genes into the target cells to 
treat a disease. The encoding gene may be 
designed to induce a useful gene expression, 
to block a harmful gene expression, or, like in 
hereditary diseases, a defective mutant allele 
is replaced with a functional one. For 
effective gene therapy it is necessary to 
deliver therapeutic genes to specific cells at 
high efficiency, express the gene for a 
prolonged period of time and ensure that the 
introduction of the therapeutic gene is not 
harmful to the target tissue.  
   There are several methods and vectors in 
use for the delivery of therapeutic nucleic 
acids into cells (Verma and Somia, 1997). 
These methods can be classified as viral and 
non-viral technologies, and a number of 
different vector systems for ocular gene 
transfer have been developed (Wright, 1997). 
Viral vectors are very efficient in transducing 
genes into cells. However, their use has been 
restricted because of immunological 
problems and risk of the insertional 
mutagenesis. In addition, producing viral 
vector can be difficult (Dobbelstein, 2003). 
Non-viral vectors are easier to engineer and 
manufacture, but significantly less efficient in 
gene delivery compared with virus-based 
vectors. In addition, the lack of their 
chromosomal integration precludes long-term 
therapeutic effects (Masuda et al., 1996).  
   The eye is an ideal organ for in vivo gene 
transfer. It is easily accessible by 
microsurgical techniques under direct 
visualization and allows local application of 
therapeutic vectors (Figure 7). Precise 
targeting of vector within the globe 
minimizes systemic dissemination and the 
possibility of unwanted systemic side effects. 
Furthermore, the optical transparency of the 
eye enables transgene expression within the 
retina and effects of treatments to be 
monitored by a variety of noninvasive 
examinations. The small size of the eye 
means that small volumes of vector 
suspensions can transduce an adequate 
proportion of cells in the target tissue. Also 
non-dividing cell populations may be 
efficiently transduced by a single dose. In 
addition, the potential risk of virus-mediated 
insertional mutagenesis is significantly lower 
in the eye than in systemic applications as the 
ocular cells targeted are relatively few in 
number. 
   Furthermore, immune responses following 
intraocular vector administration are typically 
attenuated compared to those following 
systemic administration; a relatively immune 
priviledged system protects from immune 
responses directed against vector antigens 
that might otherwise cause inflammation and 
limit transgene expression (Bennett et al., 
1996). If only one eye is treated, the 
untreated eye may serve as a useful control 
for the evaluation of the efficacy of the 
treatment. The first clinical trials in ocular 
gene transfer strategy have been focused in 
gene replacement in inherited retinal 
degeneration, Leber’s congenital amaurosis 
(Bainbridge et al., 2008; Maguire et al., 
2008).  
 
 
 
 
Figure 7. Delivery routes in ocular gene 
therapy. 
intravitreal 
delivery 
intracameral 
delivery 
subretinal 
delivery 
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2.5.1 Viral vectors 
Viruses are intra-cellular parasites with 
specialized molecular mechanisms to 
efficiently transport their genomes to the 
cells. Viruses transfect their own DNA or 
RNA efficiently into the host cells which are 
then harnessed to produce new viral particles. 
By replacing genes that are needed for the 
replication phase of viruses life cycle with 
therapeutic genes, the recombinant viral 
vectors can transduce the cell type it would 
normally infect (Figure 8). The most studied 
viruses in ocular gene therapy field are 
adenoviruses (Ad), adeno-associated viruses 
(AAV) and lentiviruses. Adenoviral vectors 
efficiently target cells of the outer retina but 
their duration of expression is limited to a 
few weeks by immune responses to the vector 
(Ali et al., 1998a; Bennett et al., 1994; 
Bennett et al., 1996; Reichel et al., 1998).   
 
 
 
 
 
AAV vectors are used for sustained 
transduction of photoreceptor cells (Ali et al., 
1996; Bennett et al., 1999; Flannery et al., 
1997). Lentiviral vectors stably transduce 
RPE cells but are less efficient than AAV in 
transducing photoreceptors (Bainbridge et al., 
2001). Retroviral vectors specifically 
transduce dividing cells and have been 
developed for proliferative and neoplastic 
intraocular disorders (Hurwitz et al., 1999; 
Sakamoto et al., 1995). Ocular tissues are 
widely distributed, and therefore the capacity 
of the vector to transfect certain tissue is 
dependent on the site of its intraocular 
administration. Delivery of AAV vectors into 
the subretinal space results in the 
transduction of photoreceptors and RPE cells, 
whereas injection of the same vector into the 
vitreous humour targets only ganglion cells in 
the inner retina (Ali et al., 1998b). 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 8. Basic principal of gene transfer with viral and nonviral vectors. 
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2.5.1.1 Adenovirus 
Adenovirus is a non-enveloped double-
stranded DNA virus with maximal carrying 
capacity of 30kb of foreign DNA (Gonçalves 
and Vries, 2006).   It is a widely used vector 
in the gene therapy field due to many 
advantages.             Ad vectors are relatively 
easy to produce, have good capacity, and 
with an appropriate promoter can mediate 
good expression levels in many types of cells 
(Campochiaro, 2007).  The transduction 
efficiency for a certain cell type varies 
depending on the serotype of the Ad vector. 
The most studied serotypes are first or 
second generation type 2 and 5 
(Campochiaro, 2007; Chuah et al., 2003). 
Adenoviruses enter the cell by CAR-receptor 
mediated endocytosis and stay in the nucleus 
as episomes (Kovesdi et al., 1997). 
Therefore, they lack the ability to integrate 
the transferred gene into chromosomal DNA 
and their presence in cells is short-lived 
typically limited to a few weeks (Jomary et 
al., 1994). Repeated vector administration 
would be required to enhance expression 
levels, but the induction of a humoral 
immune response against the capsid proteins 
precludes vector readministration (Kafri et 
al., 1998). The T-cell–mediated immune 
response of the host has been shown to play 
a role in limiting the duration of adenovirus-
mediated transgene expression in the eye 
(Hoffman et al., 1997; Reichel et al., 1998; 
Tripathy et al., 1996).  
   The wild-type adenoviral genome can be 
divided into regions that are expressed either 
early or late after the infection of the target 
cell. The early region transcription units are 
E1-E4. The early gene products have 
different functions, such as initiation and 
activation of adenoviral replication, 
suppression of endogenous host gene 
expression and activation of late adenoviral 
gene expression (L1-L5), which encode most 
of the virion structural proteins (Chuah et al., 
2003). The first generation adenoviral 
vectors have deletions in at least one of the 
early genes, which consequently impair viral 
gene expression and replication (Figure 9) 
(Kozarsky and Wilson, 1993; Krougliak and 
Graham, 1995). Whereas early generation 
adenoviral vectors still contain residual viral 
genes that contribute to inflammatory 
immune responses, the latest generation, so 
called gutless adenoviral vectors, do not 
contain any residual viral genes. Gutless 
vectors contain only inverted terminal repeat 
(ITR) parts and a packaging sequence of the 
viral genome. Gutless adenoviral vectors are 
capable of transducing also rods, and 
mediate much longer transgene expression 
(Kumar-Singh and Chamberlain, 1996). 
They have significantly improved safety and 
expression profile of adenovirus vectors 
(Ehrhardt and Kay, 2002; Schiedner et al., 
1998). However, the immune system is still 
activated with gutless vectors due to their 
interaction with antigen-presenting cells 
(Chuah et al., 2003; Thorrez et al., 2004).  
However, in clinical trials second generation 
Ad vectors were well-tolerated 
(Campochiaro et al., 2006; Chevez-Barrios 
et al., 2005).  
   Intravitreous injections of Ad vectors 
resulted in transduction of corneal 
endothelium, trabecular meshwork, iris 
pigmented epithelium, ciliary epithelium, 
and GCL in the inner retina (Budenz et al., 
1995; Mori et al., 2002c). Subretinal 
injections result in transduction of RPE cells 
and occasional Müller cells, but little or no 
transduction of retinal neurons (Bennett et 
al., 1994; Hoffman et al., 1997; Li et al., 
1994). In eyes with proliferative retinopathy, 
there is strong transduction of cells 
participating in the disease processes, which 
could be a therapeutic advantage (Mori et al., 
2002c).   
 
Figure 9. First generation adenovirus vector. 
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2.5.1.2 Baculovirus 
Baculovirus (Bv) is a double-stranded DNA 
virus more seldom used in gene therapy. It is 
a large, approximately 130 kb sized virus 
with a transgene capacity up to 100 kb of 
foreign DNA. Over 500 different types of 
baculovirus have been found and the hosts 
are most usually insects (Hu, 2005). The 
most usually used and the best known 
serotype is Autographa californica multiple 
NPV (AcMNPV). Bv cannot replicate in 
vertebrate hosts and it is capable of 
transducing differentiated, nondividing cells 
(Hu, 2006; Mähönen et al., 2007).  Bvs have 
a low cytotoxicity in mammalian cells even 
at a very high virus load and they can be 
easily produced in high titers (Airenne et al., 
2003; Laitinen et al., 2005). Bv enters 
nondividing mammalian cells by endocytosis 
and loses its envelope passing from the 
endosome to the cytoplasm. The 
nucleocapsid is then transported to the 
nucleus through the nucleopore (van Loo et 
al., 2001). Recombinant Bvs have the 
capability of transducing a variety of 
mammalian cells in vitro (Bilello et al., 
2001; Boyce and Bucher, 1996; Condreay et 
al., 1999; Ma et al., 2000; Merrihew et al., 
2001; Sarkis et al., 2000; Shoji et al., 1997; 
van Loo et al., 2001). Despite the ability to 
transduce mammalian cells in vitro, only 
limited success has been reported in vivo. 
This is most likely due to viral inactivation 
by the complement system (Hofmann and 
Strauss, 1998). In the eye, the anterior 
chamber, the subretinal space, and to a lesser 
extent, the vitreous cavity, are relatively 
immune-privileged sites (Ferguson and 
Griffith, 1997; Kaplan et al., 1999; 
Niederkorn, 1990). Antigens in these areas 
are not subject to the complement pathway 
and therefore Bvs are potential vectors for 
ocular gene therapy. Intravitreal injections of 
Bv resulted in GFP expression in the corneal 
endothelium, lens, RPE, and photoreceptor 
cells (Haeseleer et al., 2001). GFP 
expression was observed for up to two weeks 
after injection. Subretinal injection of 
BvGFP results in transduction of RPE cells. 
No alteration in ERG responses was 
observed after injection of BvGFP 
(Haeseleer et al., 2001).  
2.5.1.3 Other viruses 
Adeno-associated viruses (AAVs) are 
nonenveloped parvoviruses with linear, 
single-stranded DNA genomes that have 
many characteristics that make them 
advantageous for use as viral vectors 
(Grimm and Kay, 2003). In humans AAV 
vectors appear to invoke little immune 
response and therefore have little toxicity 
and mediate prolonged transgene expression 
(Ali et al., 1998b; Bennett et al., 1997; 
Flannery et al., 1997). AAVs have the ability 
to transduce both dividing and non-dividing 
cells and recombinant adeno-associated 
viruses have been developed that integrate 
randomly in the host genome and have been 
shown to effect stable transduction of the 
retina for more than 1 year (Bennett et al., 
1999; Hauswirth and Beaufrere, 2000). 
Limitations of AAV include difficulties to 
produce the virus, low maximal insert size of 
less than 5 kb and the induction of 
insertional mutagenesis (Miller et al., 2002). 
Moreover, AAV administration in patients 
has been associated with the induction of a 
possible cellular immune response directed 
against the processed AAV capsid antigens, 
leading to transient and acute hepatotoxicity 
(Manno et al., 2006; Zaiss and Muruve, 
2005). There are currently six known 
serotypes of AAV, of which type 2 has been 
most extensively studied as a potential 
vector (Rabinowitz et al., 2002). Different 
AAV serotypes have different virion shell 
proteins and therefore they vary in their 
ability to bind to and transfect different host 
cell types (Martin et al., 2002). Recombinant 
vectors can be generated using both capsid 
proteins and genomes from the same 
serotype or the vector genome can be 
derived from one serotype and included in 
the capsid from an alternative AAV serotype 
(Chao et al., 2000; Hildinger et al., 2001).  
   Intravitreous injections of AAV2/2 vectors 
result in transduction of ganglion cells, 
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trabecular meshwork cells and various cells 
of the inner nuclear layer, including Müller 
cells (Ali et al., 1998b; Auricchio et al., 
2001; Borrás et al., 2006; Flannery et al., 
1997; Martin et al., 2002). Subretinal 
injections of this serotype results in the 
transduction of photoreceptors and RPE 
cells, with an onset of transgene expression 
that peaks at 4 weeks after vector 
administration (Ali et al., 1996; Bennett et 
al., 1997; Flannery et al., 1997).  Subretinal 
administration of AAV5/5 or AAV2/5 also 
results in early RPE transduction, but more 
efficiently than that with AAV2/2 (Auricchio 
et al., 2001; Lotery et al., 2003; Yang et al., 
2002).   
   Lentivirus-based vectors are attractive 
candidates for ocular gene transfer because 
they efficiently transduce a variety of 
nondividing cells with little or no host 
response resulting in long-term transgene 
expression (Naldini et al., 1996; Poznansky 
et al., 1991). Human immunodeficiency 
virus-1 (HIV-1) and feline 
immunodeficiency virus (FIV) based 
lentiviral vectors efficiently transduce the 
corneal endothelium and trabecular 
meshwork following delivery into the 
anterior chamber (Challa et al., 2005; 
Loewen et al., 2004). Subretinal injection in 
rodents led to stable transgene expression in 
the RPE cells for at least 2 years (Cheng et 
al., 2005; Loewen et al., 2004; Tschernutter 
et al., 2005). HIV-1 based lentiviral vector 
has been shown to mediate therapeutic 
effects in retinal degenerations where RPE is 
involved (Miyazaki et al., 2003; Tschernutter 
et al., 2005). Lentivirus-mediated 
transduction of photoreceptor cells appears 
to be less predictable than transduction of 
RPE cells, but is reported to occur under 
certain circumstances depending on retinal 
maturity, the used promoter and anatomical 
barriers. Photoreceptor transduction is 
evident following subretinal vector delivery 
in neonatal rodents, but the efficiency of 
photoreceptor transduction in adults is 
relatively low (Kostic et al., 2003). The 
efficiency of photoreceptor cell transduction 
in adults is improved in locally traumatized 
retinas suggesting that anatomical barriers to 
tissue penetration by vector particles may be 
a limiting factor (Bainbridge et al., 2001; 
Gruter et al., 2005; Kostic et al., 2003). 
Vectors based on nonprimate lentiviruses 
such as FIV and bovine immunodeficiency 
virus (BIV) have transduction efficiencies 
and durations of expression in ocular tissues 
that are comparable to HIV-1 based vectors 
and may provide alternatives with potential 
safety advantages (Bainbridge et al., 2001; 
Cheng et al., 2005; Loewen et al., 2004; 
Molina et al., 2004). BIV is a lentivirus that 
is not known to cause human disease. 
Subretinal injection of a      BIVGFP vector 
resulted in a prolonged transduction of RPE 
cells with no inflammatory response 
(Takahashi et al., 2002).   
2.5.2 Non-viral vectors 
Problems associated with virus vectors have 
led to the development of non-viral methods 
(Abdallah et al., 1995; Glover et al., 2005; 
Niidome and Huang, 2002). These 
techniques are categorized into two general 
groups. Naked DNA delivery by a physical 
method, including electroporation, gene gun 
and ultrasound employ a physical force that 
permeates the cell membrane and facilitates 
intracellular gene transfer (Heller et al., 
2005; Lawrie et al., 2000; Liu et al., 1999; 
Neumann et al., 1982; Wolff et al., 1990; 
Yang et al., 1990; Yang and Sun, 1995; 
Zhang et al., 1999). The chemical 
approaches use synthetic or naturally 
occurring compounds such as cationic 
polymer and lipid as carriers to deliver the 
transgene into cells (Liu et al., 2003; Neu et 
al., 2005; Niidome and Huang, 2002).  
Advantages of non-viral systems include 
their reduced immunogenicity, unlimited 
size of therapeutic expression cassette and 
improved safety profiles (Li and Huang, 
2000). In addition, non-viral vectors are 
easier and less expensive to manufacture 
(Nabel et al., 1993; Stewart et al., 1992). 
However, non-viral approaches have been 
suffering from inefficient delivery resulting 
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in transient transgene expression (Dass, 
2004). In addition, vitreous humour has been 
shown to limit nonviral gene delivery to RPE 
cells substantially in vitro (Peeters et al., 
2005; Pitkanen et al., 2003). 
2.5.2.1 Plasmids  
Simple injection of plasmid DNA directly 
into a tissue without additional help from 
either a chemical agent or a physical force is 
able to transfect cells (Li and Huang, 2000).  
Specific or nonspecific receptors on the cell 
surface that bind and internalize DNA have 
been implicated as a mechanism (Gao et al., 
2007).  However, owing to rapid degradation 
by nucleases in the serum and clearance by 
the mononuclear phagocyte system, the 
expression level and the area after injection 
of naked DNA are generally limited (Li and 
Ma, 2001). Following intravitreous injection 
of naked plasmid in mice, expression of the 
reporter gene was observed in retinal 
ganglion cells for only one day (Hangai et 
al., 1998a).  However, subretinal injection of 
a reporter gene encoding plasmid did not 
lead to gene expression (Kachi et al., 2005).  
2.5.2.2 Physical methods 
Various physical manipulations have been 
used to improve the efficiency of non-viral 
gene transfer. The transduction efficiency of 
non-viral vectors in the retina can be 
substantially improved by adjunctive 
electroporation. Electroporation is the use of 
electric fields to facilitate the penetration of 
macromolecules into cells; it is based upon 
the observation that electric fields can alter 
the structure and permeability of cell 
membranes (Coster, 1965). Following 
intravitreal injection of plasmid DNA 
electroporation results in short-lived but 
efficient transduction of retinal ganglion 
cells (Ishikawa et al., 2005). Electroporation 
of plasmid DNA delivered to the subretinal 
space in neonatal rodents leads to efficient 
reporter gene expression in photoreceptors, 
bipolar cells and Müller cells that is 
sustained for at least 50 days (Matsuda and 
Cepko, 2004). Electroporation can be 
associated with variable adverse effects on 
normal ocular structures resulting in 
inflammation, cataract, retinal degeneration 
and phthysis (Bainbridge et al., 2006).                  
   Gene gun technique consists of 
“bombarding” a tissue with gold or tungsten 
bullets covered with DNA. It is potentially 
applicable for the treatment of ocular surface 
diseases and particularly for corneal diseases 
(Bloquel et al., 2006). Ultrasound can alter 
the permeability of plasma membrane 
transiently and thereby facilitate DNA 
uptake (Bloquel et al., 2006). A number of 
groups have demonstrated the utility of these 
various modalities of ultrasound in 
enhancing the delivery of plasmid DNA 
(Chen et al., 2003; Danialou et al., 2002; 
Sonoda et al., 2006; Taniyama et al., 2002).  
2.5.2.3 Lipoplex 
Lipofection reagents are molecules 
composed of phospholipids that contain both 
hydrophobic and hydrophilic domains. 
These reagents form complexes with DNA 
in a physicochemical manner by electrostatic 
interactions between the positively charged 
(cationic) lipid and the negatively charged 
DNA (Felgner and Ringold, 1989). The 
DNA condenses with the lipofection reagent 
in a non-enzymatic fashion to form lipid/ 
DNA complexes that can be used to deliver 
foreign DNA to cells in vitro and in vivo 
(Bebok et al., 1996; Caplen et al., 1995; 
Chaum et al., 2000; Chaum, 2001; Felgner et 
al., 1987; Gershon et al., 1993; Kukowska-
Latallo et al., 1996; Masuda et al., 1996). 
Virus-coated liposomes have also been used 
to transfer genes to the anterior segment, 
retina, and choroidal neovascular tissue 
(Hangai et al., 1996; Hangai et al., 1998b; 
Otsuji et al., 2000). The lipid/DNA 
complexes enter the cell by endocytosis 
(Wrobel and Collins, 1995). After 
endocytosis, much of the DNA is degraded 
by fusion of the endosome with lysosomes 
(Friend et al., 1996). However, some of the 
DNA is released into the cytoplasm from the 
endosomes and makes its way to the nucleus 
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probably by a concentration-dependent 
manner (Friend et al., 1996; Xu and Szoka, 
1996). Active transport of DNA to the 
nucleus following lipofection has not been 
demonstrated (Chaum and Hatton, 2002). 
Disadvantages of lipofection include poor 
target selectivity, reduced efficiency 
compared to viral vectors, and short duration 
of expression. Transient transgene 
expression results from the episomal status 
of the plasmid vector after it reaches the 
nucleus, with low frequency of integration 
into the host genome. However, a small 
percentage of transfected retinal cells do 
show transduction with sustained transgene 
expression in vitro (Chaum et al., 2000).  
2.5.2.4 Transposons 
Transposable elements are non-viral gene 
delivery vehicles found ubiquitously in 
nature. Transposon-based vectors have the 
capacity of stable genomic integration and 
long-lasting expression of transgene 
constructs in cells. Transposons are discrete 
segments of DNA that have the distinctive 
ability to move from one genetic location to 
another in a genome (Ivics and Izsvak, 
2006). Transposon integration into 
chromosomes provides the basis for long 
term transgene expression in transgenic cells 
and organisms. The only known, naturally 
occurring, active transposable element of 
vertebrate origin is the Tol2 transposon 
isolated from the medakafish (Koga et al., 
1996). In addition, Tc1/mariner-type, active 
elements from transposon fossils found in 
fish genome were reconstructed and named 
Sleeping Beauty and Frog Prince (Ivics et 
al., 1997; Miskey et al., 2003). Sleeping 
Beauty transposition is efficient in cells of 
different vertebrate classes in tissue culture 
(Huang et al., 2006; Izsvák et al., 2000). 
Transposons have not been used in ocular 
gene therapy. 
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Table 2. Vectors in gene therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vector Advantages Disadvantages Gene expression after 
Intravitreal 
injection 
Subretinal 
injection 
Plasmid 
DNA  
and 
complexes 
Easy to produce 
Safe 
Low transduction 
efficiency 
Transient expression 
Ganglion cells No gene 
expression 
Adeno- 
virus 
Easy to produce 
High transduction 
efficiency 
Broad host spectrum 
 
Immunogenic 
Transient expression 
Repeated injections 
impossible 
Corneal endothelium 
Trabecular meshwork 
Ciliary epithelium 
Ganglion cells 
Occasional 
Müller cells  
RPE 
 
AAV Broad host spectrum  
Long expression 
Not associated with 
human diseases 
 
Difficult to produce  
Limited DNA capacity 
Trabecular meshwork  
Ganglion cells 
Müller cells  
 
RPE 
Photoreceptors 
 
Baculo- 
virus 
Easy to produce 
Not associated with 
human diseases 
High DNA capacity 
Inactivation by 
complement fractions  
Moderate transduction 
efficacy 
Transient expression 
Corneal endothelium 
Lens 
Photoreceptor cells  
RPE 
 
RPE 
Lentivirus Broad host spectrum 
Long expression 
Random integration of 
DNA 
Difficult to produce  
Low transduction 
efficiency 
Limited DNA capacity 
No gene expression RPE 
Photoreceptors 
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2.6 ANTIANGIOGENIC AGENTS FOR 
OCULAR NEOVASCULARIZATION  
2.6.1 PEDF 
One of the most studied proteins that has 
been shown to inhibit ocular 
neovascularization is pigment epithelium 
derived factor (PEDF). It was first isolated 
from cultured RPE cells as a neurotrophic 
factor (Tombran-Tink et al., 1991). PEDF is a 
50 kDa glycoprotein which belongs to the 
serine protease inhibitor (serpin) family in the 
plasminogen system, but it lacks the protease 
inhibitor activity normally seen in serpins 
(Becerra et al., 1995; Steele et al., 1993). 
PEDF has been shown to inhibit the 
migration of ECs in vitro in a dose-dependent 
manner more effectively than angiostatin or 
endostatin (Dawson et al., 1999).  It also 
promotes survival of cultured neurons and 
protects photoreceptors from the effects of 
excessive light exposure (Araki et al., 1998; 
Bilak et al., 1999; Cao et al., 2001; Steele et 
al., 1993). In the eye, PEDF is normally 
found in high concentrations in the vitreous 
humour, the lens and the cornea and it could 
be partly responsible for the avascularity of 
these tissues (Dawson et al., 1999; Wu and 
Becerra, 1996). PEDF is produced by the 
RPE, cornea and ciliary epithelium 
(Tombran-Tink et al., 1995). Oxidative stress 
is known to induce a dose-dependent 
reduction in the expression of PEDF (Cao et 
al., 1999). The vitreous concentration of 
PEDF declines with increasing age and is 
more marked in patients with AMD 
(Holekamp et al., 2002). It is not clear 
whether this is due to decreased synthesis or 
increased proteolytic activity in the vitreous 
(Wu and Becerra, 1996).  In addition, the 
levels of intraocular PEDF have been shown 
to decrease with advancing stages of diabetic 
retinopathy (Boehm et al., 2003; Ogata et al., 
2001a; Ogata et al., 2002; Spranger et al., 
2001). Systemic delivery of recombinant 
PEDF inhibited ischemia-induced retinopathy 
in animal models (Duh et al., 2002; Stellmach 
et al., 2001). Subretinal transplanation of 
autologous iris pigment epithelial cells 
expressing PEDF inhibited laser-induced 
CNV in rats (Semkova et al., 2002). In the rat 
model of ischemia-induced retinopathy, an 
increased VEGF/PEDF ratio correlated with 
the presence of retinal neovascularization 
(Gao et al., 2001).  Intraocular AAV-
mediated gene transfer of PEDF has also 
been shown to inhibit retinal and choroidal 
neovascularization (Auricchio et al., 2002; 
Mori et al., 2002d; Raisler et al., 2002). 
Furthermore, intravitreous or subretinal 
injection of adenoviral vector expressing 
human PEDF (AdPEDF) suppressed the 
development of retinal or choroidal 
neovascularization and also caused regression 
of established neovascularization (Mori et al., 
2001b; Mori et al., 2002b).  Injection of 
AdPEDF beneath the conjunctiva along the 
outer border of the sclera resulted in 
transduction of episcleral cells that produced 
PEDF on the outside of the eye (Gehlbach et 
al., 2003a). The PEDF penetrated the sclera 
resulting in high levels in the choroid that 
caused regression of CNV. Subconjunctival 
injection of AdPEDF also inhibited CNV in 
pigs (Saishin et al., 2003b). Also AdPEDF 
phase I clinical trial in patients with advanced 
CNV due to AMD have been done. In this 
study, there were no serious adverse events 
and a significant proportion of the patients 
had an improvement in lesion size from 
baseline (Campochiaro et al., 2006).   
2.6.2 sFlt-1 
Soluble (s)Flt-1 is a naturally occurring 
protein antagonist of VEGF formed by 
alternative splicing of the pre-mRNA for the 
full length VEGFR-1 (He et al., 1999; 
Kendall et al., 1996). The angiostatic activity 
of sFlt-1 results from inhibition of VEGF by 
two mechanisms. It causes both sequestration 
of VEGF to which it binds with high affinity 
and forms inactive heterodimers with 
VEGFR-1 and VEGFR-2 (Kendall et al., 
1996). It is not clear whether sFlt-1 has a role 
in normal eyes, but several studies have 
tested the effect of overexpression of sFlt-1 in 
ocular neovascularization models (Gehlbach 
et al., 2003b; Honda et al., 2000; Lai et al., 
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2001; Rota et al., 2004). Inhibition of VEGF 
by repeated intravitreal injections of 
recombinant sFlt-1 chimeric proteins and 
antisense oligodeoxynucleotides have been 
shown to reduce retinal neovascularisation in 
OIR mouse model (Aiello et al., 1995a; 
Robinson et al., 1996). Intraocular injection 
of AdsFlt-1 suppressed retinal or choroidal 
neovascularization (Bainbridge et al., 2002; 
Honda et al., 2000; Rota et al., 2004).  
Periocular injection of AdsFlt-1 resulted in 
transduction of episcleral cells, penetration of 
the sclera and high levels of AdsFlt-1 in the 
choroid, which markedly suppressed CNV 
(Gehlbach et al., 2003b). Long-term 
suppression of CNV was achieved with 
intraocular injection of AAVsFlt-1 in mice 
and monkeys (Bainbridge et al., 2002; Lai et 
al., 2005; Lai et al., 2002).   
2.6.3 RNA interference 
The production of growth hormones can be 
inhibited by RNA interference. It is a natural 
mechanism to inhibit the intracellular 
production by silencing gene coding for a 
specific protein (Elbashir et al., 2001). Small 
interfering RNA (siRNA) is a double 
stranded RNA, which consists of 21-22 
nucleotides. After being further processed to 
a RNA-induced silencing complex (RISC) by 
intracellular enzymes, the fragment binds 
specifically to messenger RNA (mRNA), 
causing cleavage and further digestion of the 
mRNA. The RISC can then bind to other 
mRNA molecules and the process is repeated 
multiple times resulting in a very efficient 
overall inhibition of the production of the 
targeted protein (Schmidt-Erfurth and 
Pruente, 2007). Bevasiranib, siRNA targeting 
VEGF, has been shown to inhibit retinal 
neovascularization in a mouse model (Reich 
et al., 2003). In non-human primates the area 
of laser induced CNV was significantly 
decreased with intravitreal injection of 
bevasiranib (Tolentino et al., 2004). In the 
phase II randomized doubleblinded CARE 
(Cand5 Anti-VEGF RNAi evaluation) study 
designed to assess the safety and efficacy of 
bevasiranib, 129 patients with CNV due to 
AMD were randomized to receive three 
different intravitreal doses of bevasiranib at 
baseline and at 6 weeks. No local or systemic 
serious adverse events were found. However, 
there was evidence of continuing 
deterioration during the first three weeks of 
treatment. The phase III COBALT study is 
currently assessing the safety and efficacy of 
bevasiranib administered every 8 or 12 weeks 
as maintenance therapy following 3 monthly 
injections of ranibizumab in 330 patients with 
AMD.  
   Intravitreous or periocular injection of 
AGN211745 (Sirna-027), siRNA directed 
against VEGFR-1, resulted in significant 
reductions in the area of neovascularization 
in mouse models of retinal and choroidal 
neovascularization (Shen et al., 2006). A 
phase I dose-escalation study with 
AGN211745 in 26 patients with AMD 
showed single intravitreal injection of 
siRNA-027 to be safe and well tolerated. 
Visual acuity stabilization was achieved in 
92% of patients at 3 months and decreased 
foveal thickness was seen in some patients. A 
phase II 24-month single blinded safety and 
efficacy study is currently in enrolment 
(Chappelow and Kaiser, 2008).   
   RTP801i-14 (PF-4523655) is a siRNA 
designed to inhibit the expression of the 
hypoxia-inducible gene RTP801. The 
RTP801 gene is upregulated in response to 
ischemia, hypoxia and oxidative stress both 
in vitro and in vivo (Shoshani et al., 2002). It 
has been shown to promote neuronal cell 
apoptosis and the generation of ROS in vitro 
by a mechanism that is independent of 
growth factors such as VEGF (Ellisen et al., 
2002; Shoshani et al., 2002). In both 
RTP801-knockout and therapeutic mouse and 
primate models of laser-induced CNV, 
inhibition of RTP801 expression leads to 
inhibition or reduction of CNV and vessel 
leakage more efficiently than anti-VEGF 
drugs (Brafman et al., 2004; Nozaki et al., 
2006). In addition, knock out of RTP801 
ameliorates diabetes–induced retinal vascular 
permeability and ERG abnormalities in 
diabetic mice (Timothy et al., 2005). Because 
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it has anti-inflammatory and antiapoptotic 
properties it may also be useful for the 
treatment of dry AMD. Results from a Phase 
I/II trial showed that RTP801i-14 was safe 
and well tolerated in patients with wet-AMD 
who failed to respond to currently approved 
therapies. The phase II prospective, 
randomized, dose-ranging study is currently 
evaluating the safety and efficacy of 
RTP801i14 versus laser therapy in 160 
patients with diabetic macular edema 
(ClinicalTrials, 2009b).  
2.6.4 Aflibercept  
Aflibercept, VEGF Trap, is a receptor decoy 
with a higher affinity for VEGF than native 
VEGF receptors or any of the currently 
available anti-VEGF drugs. It is a soluble 
protein, combining ligand–binding elements 
from the extracellular domains of VEGFR-1 
and VEGFR-2 fused to the Fc constant region 
of immunoglobulin G1. The molecule binds 
to all members of VEGF family with high 
affinity, but does not non-specifically attach 
to any components of the ECM. It has been 
shown to penetrate through all retinal layers. 
In a mouse model with laser induced CNV, 
aflibercept induced the regression of CNV by 
85% within 10 days (Saishin et al., 2003a). 
Furthermore, the CNV completely 
disappeared in a large percentage of eyes. 
Intravitreal administration of aflibercept 
significantly reduced retinal vascular 
permeability in diabetic rat model (Cao et al., 
2006). Data from a phase I, randomized, 
double-blind, placebo-controlled, ascending-
dose trial of 25 patients with AMD showed a 
dose-dependent decrease in retinal thickness 
in patients who received intravenous 
aflibercept (Nguyen et al., 2006). However, 
dose-limiting toxicity (hypertension in one 
patient and proteinuria in another patient) 
was observed and the study and further 
clinical development of systemic aflibercept 
for ocular disease was halted (Nguyen et al., 
2006). The safety, tolerability and bioactivity 
of intravitreal aflibercept for the treatment of 
neovascular AMD was evaluated in the two-
part CLEAR-IT-1 (Clinical Evaluation of 
Anti-angiogenesis in the Retina Study). In 
part 1, 21 patients were randomized to 
receive one of six doses of aflibercept as a 
single intravitreal injection at baseline, then 
assessed at 1, 2, 4 and 6 weeks using ETDRS 
(Early Treatment Diabetic Retinopathy 
Study) best-corrected visual acuity, FAG and 
OCT. Aflibercept was well tolerated and 
there were no adverse events. At 6 weeks 
visual acuity remained stable or improved in 
95% of patients and the total area of CNV 
decreased 35%. Reduction in central 
thickness in OCT was also seen (Benz et al., 
2007).   
   A randomized, double-blind phase III trial 
of aflibercept in approximately 1200 patients 
with the neovascular form of wet AMD, 
VIEW 1 (VEGF Trap: Investigation of 
Efficacy and safety in Wet age-related 
macular degeneration) study will evaluate the 
safety and efficacy of intravitreal aflibercept 
at different doses administered at two 
different dosing intervals compared with 0.5 
mg ranibizumab administered every 4 weeks 
(ClinicalTrials, 2009a). 
   Additionally, a phase I trial of aflibercept in 
five patients with diabetic macular edema has 
been done. Results indicated that a single 4 
mg injection resulted in a marked decrease in 
mean central retinal thickness and mean 
macular volume. Aflibercept was well 
tolerated, and there were no drug-related 
serious adverse events (Do et al., 2007).   
2.6.5 Endostatin 
Endostatin is a cleavage product of collagen 
XVIII that inhibits EC adhesion, migration 
and proliferation, as well as the induction of 
apoptosis (O'Reilly et al., 1997). It has been 
studied most widely in cancer therapy. In the 
eye, endostatin has been found in the lens 
epithelium and in the ciliary body. In the 
retina, endostatin has been found in the inner 
limiting membrane. It has also been detected 
in the lens capsule and all border membranes 
lining the aqueous humor including the 
anterior surface of the iris. These findings 
suggest that there are specific endostatin 
expressing structures forming a barrier 
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around the anterior chamber and the vitreous, 
which may prevent ocular blood vessels from 
sprouting into these avascular compartments 
(Ohlmann et al., 2005). In collagen XVIII 
gene knockout mice, deficient endostatin 
production causes delayed regression of 
blood vessels in the vitreous and abnormal 
outgrowth of retinal vessels (Fukai et al., 
2002). In addition, the age-dependent vision 
loss in these mutant mice is associated with 
pathological accumulation of deposits under 
the RPE, as seen in early stages of AMD in 
humans suggesting that endostatin is an 
important endogenous regulator of 
vasculature formation and tissue development 
in the eye (Marneros et al., 2004). Endostatin 
levels in the vitreous and aqueous humor are 
decreased in patients with diabetic 
retinopathy and negatively correlate with the 
severity of retinopathy and VEGF levels 
(Funatsu et al., 2001; Noma et al., 2002). 
Endostatin is also reduced in Bruch's 
membrane and choriocapillaris basement 
membrane in AMD subjects compared to 
aged normal human subjects (Bhutto et al., 
2004).  Intravenous injection of adenoviral 
vectors encoding endostatin increased the 
serum level of endostatin and inhibited laser-
induced CNV (Mori et al., 2001a). In OIR 
mouse model intraocular injection of AAV 
endostatin inhibited ischemia-induced retinal 
neovascularization (Auricchio et al., 2002).  
Injection of endostatin into the eyes of the 
VEGF transgenic mice demonstrated that 
endostatin significantly reduced the VEGF-
induced retinal vascular hyper-permeability 
and inhibited retinal neovascularization 
(Takahashi et al., 2003).   
2.6.6 Angiostatin 
Angiostatin, a 38-45 kDa internal fragment of 
plasminogen, is a potent inhibitor of 
angiogenesis, which selectively inhibits 
proliferation and induces apoptosis in ECs. It 
is a cleavage product of fibrinogen that 
inhibits tumor angiogenesis and 
downregulates VEGF (O'Reilly et al., 1994).  
As a naturally occurring peptide, it is not 
likely to stimulate an immunogenic response 
(Cao, 2001). In the patients with proliferative 
diabetic retinopathy, significant elevation of 
vitreal angiostatin levels and decrease of 
VEGF concentration in the vitreous was 
observed in those who had previous laser 
photocoagulation, suggesting that local 
release of angiostatin and down-regulation of 
VEGF mediate the therapeutic effects of 
retinal photocoagulation in proliferative 
diabetic retinopathy (Spranger et al., 2000).  
Intravitreal delivery of AAV encoding 
angiostatin reduced vascular leakage in a 
diabetic rat model (Shyong et al., 2007). In 
OIR mouse model, systemic and intravitreal 
injections of angiostatin before the 
appearance of retinal neovascularization 
resulted in significantly fewer pre-retinal 
vascular cells, suggesting a preventive effect 
of angiostatin on the retinal neovessel 
formation (Drixler et al., 2001; Meneses et 
al., 2001). Subretinal or intravitreous 
injection of AAV or lentiviral vector 
expressing angiostatin has been shown to 
suppress retinal and choroidal 
neovascularization (Igarashi et al., 2003; Lai 
et al., 2001; Raisler et al., 2002). However, in 
normal neonatal mice, angiostatin does not 
affect any physiological development of 
retinal vasculature, indicating no toxicities to 
normal vasculature with the angiostatin 
administration (Drixler et al., 2001).   
2.6.7 Rapamycin 
Rapamycin, also known as sirolimus, targets 
the protein kinase mammalian target of 
rapamycin (mTOR), which regulates cell 
growth and metabolism. In addition to 
possessing anti-inflammatory, anti-fibrotic 
and anti-proliferative properties, rapamycin 
acts as an antiangiogenic agent decreasing 
VEGF and transforming growth factor-β1 
(Guba et al., 2002). Rapamycin also exerts an 
antiangiogenic effect by downregulating HIF-
1α, which effectively decreases VEGF 
production and inhibits VEGF induced EC 
proliferation. In preclinical studies, 
rapamycin inhibited VEGF-induced 
hyperpermeability in mice and reduced CNV 
in a murine laser-induced model of CNV 
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(Dejneka et al., 2004; Kleinman et al., 2007). 
In the phase I dose escalation study in 30 
patients with CNV and 50 patients with 
diabetic macular edema, single intravitreal 
injection of rapamycin was well tolerated and 
functional and anatomical improvements 
were seen (Blumenkranz et al., 2008; Dugel 
et al., 2008).  
2.7 ANTI-VEGF THERAPY FOR 
OCULAR NEOVASCULAR DISEASES 
 
VEGF is an attractive target in anti-CNV 
therapy because of its important role in ocular 
angiogenesis. Anti-VEGF treatments of 
neovascular AMD and other ocular 
neovascular diseases have beneficial effects 
on disease progression. However, intravitreal 
administration of current treatment molecules 
has also several risks including 
endophthalmitis, retinal detachment, cataract 
and uveitis. In patients treated for up to 2 
years with pegaptanib the drug was well 
tolerated in the eye. Endophthalmitis 
occurred at a rate of 0.16% per injection, 
retinal detachment at 0.08% per injection, 
and traumatic cataract 0.07% per injection 
during the first year of study (D’Amico, 
2006).      Aseptic technique, including 
periocular and ocular surface preparation, lid 
speculum, and drape were found to be 
essential (D’Amico, 2006). With improved 
aseptic techniques,       the incidence of 
endophthalmitis was decreased to 0.10% per 
injection within the second year of the study.  
Intravenous bevacizumab in cancer therapy 
has shown systemic side-effects including 
hypertension, increased rate of 
thromboembolic events, gastrointestinal 
perforations, myocardial infarctions, and 
death (Hurwitz et al., 2004; Miller et al., 
2005). Intravitreal injections lead to 
detectable but significantly lower serum 
levels of ranibizumab and pegaptanib than 
with intravenous administration (Gaudreault 
et al., 2005; Siddiqui and Keating, 2005). 
There was no evidence of an increase in 
deaths, hypertension or thromboembolic 
events in the 2-year safety data from the 
VISION trial (D’Amico, 2006). In the first 
year of the ANCHOR and MARINA trials 
the risk of myocardial infarction and stroke 
was slightly higher in the 0.5 mg ranibizumab 
compared to the control group.  
   Current anti-VEGF drugs have a relatively 
short half-live leading to repeated 
administrations (Cao, 2001). The long term 
effects of these multiple injections on the 
structure and function of eye are still largely 
unknown. The risk of complications is 
anyway increased with the number of 
injections, and safer and more sustained 
regimens need to be developed for intraocular 
antiangiogenic therapy.  
2.7.1 Pegaptanib 
Pegaptanib is a pegylated ribonucleic acid 
oligonucleotide aptamer approved as the first 
antiangiogenic aptamer for use of wet AMD 
by the FDA in 12/2004 followed by an 
approval by the EMEA in 1/2006. Aptamers 
are oligonucleotides designed to bind to 
specific molecules based on their three-
dimensional structure. Aptamers rarely evoke 
immune responses (Eyetech Study Group, 
2002). Pegaptanib binds specifically to 
VEGF-A165 and inhibits angiogenesis and 
pathologic leakage (Moshfeghi and Puliafito, 
2005). The recommended dose of pegabtanib 
is 0.3 mg and the drug is administred 
intravitreally every six weeks as the molecule 
is rapidly degraded enzymatically by 
intraocular nucleases (Schmidt-Erfurth and 
Pruente, 2007). The VISION trial, designed 
as two parallel phase III double-masked, 
sham-controlled, dose-ranging studies 
included a total of 1186 AMD patients. 
Intravitreal injections were performed on a 
fixed regular schedule with six weeks 
intervals. After one year, 70% of pegabtanib 
treated eyes versus 55% of control eyes lost 
less than 15 letters in visual acuity 
(Gragoudas et al., 2004). At two years, 59% 
of eyes treated with a dose of 0.3 mg 
pegabtanib lost less than 15 letters compared 
to 45% of standard care treated eyes 
(D’Amico, 2006). Patients discontinuing 
pegabtanib treatment after the first year 
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experienced an additional mean loss of 15 
letters in 27% of eyes. These results suggest 
that pegabtanib injections need to be 
continued over a period of at least two years 
in order to maintain a small benefit consisting 
of a mean loss of two lines.  
   Pegaptanib has also been studied in diabetic 
retinopathy. Safety and efficacy of 
pegaptanib were assessed in a randomized, 
sham-controlled, double-masked Phase II 
trial enrolling 172 diabetic subjects with 
diabetic macular edema. Intravitreous 
injections were administered every six weeks. 
At Week 36, 0.3 mg pegaptanib was 
significantly superior to sham injections. 34% 
of patients gained ≥10 letters and also change 
in mean central retinal thickness decreased 
significantly (Macugen Diabetic Retinopathy 
Study Group, 2005). In addition, a 
retrospective subgroup analysis revealed that 
pegaptanib treatment led to the regression of 
baseline retinal neovascularization in 8 of 13 
patients with proliferative diabetic 
retinopathy (Macugen Diabetic Retinopathy 
Study Group, 2006).  
2.7.2 Ranibizumab 
Ranibizumab is a recombinant humanized fab 
fragment derived from a monoclonal 
antibody. It was approved by the FDA for the 
treatment of all lesion types in neovascular 
AMD at a dose of 0.5 mg in 7/2006 and by 
the EMEA in the first quarter of 2007. It has 
a rather small molecular size of 48 kDa 
which ables the drug to penetrate the inner 
limiting membrane and reach the subretinal 
space when injected intravitreally. It binds all 
biologically active isotypes of VEGF with 
high affinity (Chen et al., 1999).  Intravitreal 
injections of ranibizumab prevented 
formation of CNV in animal models, and 
decreased leakage of already formed CNV 
with no significant toxic effects (Husain et 
al., 2005; Krzystolik et al., 2002).  The half-
life of ranibizumab is 2–4 days, resulting in a 
rapid systemic clearance and high systemic 
safety. A randomized, sham-controlled phase 
III MARINA study included 716 patients 
with minimally classic or occult CNV. 
Patients were randomized into two treatment 
and one sham group. Injections were given in 
monthly intervals over 24 months. At the 12 
month visit, 95% of treated eyes had 
maintained stable vision within three lines 
compared to 62% of control eyes. After 24 
months, 90% of eyes in the 0.5 mg group 
versus 53% in the control group 
demonstrated stable vision (Rosenfeld et al., 
2006). The ANCHOR study was a 
prospective, randomized phase III trial 
including 423 patients with predominantly 
classic CNV. Fixed monthly injections of 0.3 
or 0.5 mg ranibizumab were compared to the 
photodynamic therapy (PDT). At one year, 
96% of all eyes treated with 0.5 mg 
ranibizumab had lost less than three lines 
versus 64% of PDT-treated eyes (Brown et 
al., 2006). The PIER study included 182 
patients with all lesion subtypes of CNV. The 
aim of this study was to evaluate the              
efficacy and safety of ranibizumab initially 
administered monthly for three injections 
followed by a fixed regimen of re-treatments 
in three month intervals. Overall, patients 
treated with ranibizumab remained stable at 
baseline visual acuity for 12 months. 
However, the proportion of gainers with 3 
lines was only 13% compared to 34% of 
three line gainers in MARINA and 40% in 
ANCHOR. For the majority of eyes, the fixed 
quarterly regimen was not sufficient and 
recurrence was not treated adequately. This 
observation highlights the importance of an 
individualized re-treatment regimen based on 
an individualized diagnostic monitoring 
(Schmidt-Erfurth and Pruente, 2007). 
2.7.3 Bevacizumab 
Bevacizumab is a full length recombinant, 
humanized antibody of a molecular weight of 
149-kDa which binds to all VEGF isoforms. 
Like ranibizumab, the drug reduces 
angiogenesis and vascular permeability. The 
drug was originally developed to target 
pathologic angiogenesis in tumors and was 
approved by the FDA for the treatment of 
metastatic colorectal cancer. Due to its 
substantially larger molecular weight, local 
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and systemic clearance of bevacizumab may 
be delayed, resulting in an extended 
durability of the treatment, but associated 
with higher systemic toxicity (Schmidt-
Erfurth and Pruente, 2007). Experimental 
studies showed no toxic effect of a 2.5 mg 
dose to the retina in a rabbit model, however, 
toxic effects were found following the 
application of a dose of 5 mg (Manzano et al., 
2006). Using immunohistochemistry, full 
thickness penetration following intravitreal 
injection of 500 µg bevacizumab was 
demonstrated in the rabbit retina (Shahar et 
al., 2006). In a phase I SANA study, 15 AMD 
patients were given bevacizumab 
intravenously in 2-week intervals. This 
resulted in a significant improvement in 
visual acuity, OCT and angiographic 
outcomes at a follow-up of 12 weeks 
(Michels et al., 2005). A mild elevation in 
systolic blood pressure was seen as a 
systemic adverse event, which was reportedly 
controlled by anti-hypertensive medication. 
Promising results have been reported from a 
case series including 266 AMD patients 
treated with intravitreal injections of 
bevacizumab at a dose of 1.25 mg. Within 
three months, improvement in function and 
visual acuity was seen in 38% of treated 
patients and the mean central retinal 
thickness decreased significantly (Spaide et 
al., 2006). Also improvement in the 
multifocal-ERG responses consistent with 
photoreceptor recovery was seen (Shahar et 
al., 2006). Small studies with intravitreal 
bevacizumab have also been done in diabetic 
patients (Avery et al., 2006; Spaide and 
Fisher, 2006). Intravitreal bevacizumab was 
given in monthly intervals and functional 
benefit was seen with mean visual acuity 
improvement  after two months (Avery et al., 
2006). Also other neovascular diseases have 
been treated with bevacizumab with positive 
effects (Avery, 2006; Iturralde et al., 2006; 
Spaide and Fisher, 2006). Bevacizumab 
appears to have a beneficial effect in the off-
label treatment of intraocular 
neovascularization at least based on 
retrospective case series. 
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3 AIMS OF THE STUDY  
 
The aim of the study was to determine factors involved in the pathogenesis of proliferative 
diabetic retinopathy and retinal neovascularization. Furthermore, the differences between type 1 
and type 2 diabetics were studied. From the basis of these results, we evaluated the effects of 
overexpression of vascular endothelial growth factors -A and –D in the rabbit eye. In addition, 
we evaluated adenovirus and baculovirus vectors for their efficacy, safety and distribution in 
ocular gene therapy in order to develop more sustain therapies for ocular neovascular diseases. 
Finally, ocular phenotype of IGF-II/LDLR–/–ApoB100/100 mice was studied.  
 
The following questions were addressed:  
 
-Which factors are involved in proliferative diabetic retinopathy? Are there differences between 
type 1 and type 2 diabetic patients? (I)  
 
-What are the effects of VEGF-A165 and VEGF-D∆N∆C in ocular tissues? (II-III)  
 
-What is the efficacy, safety and distribution of adenoviral and baculoviral vector after 
intravitreal gene transfer? (II-III) 
 
-What is the ocular phenotype of diabetic IGF-II/LDL–/–ApoB100/100mice? (IV) 
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4 MATERIALS AND METHODS 
 
The following tables and figure contain the 
summary of the materials and methods used 
in this study. The materials and methods have 
been described in details in the original 
publications (I-III) and in the manuscript 
(IV). 
 
Informed consent was obtained from the 
subjects after explanation of the nature and 
possible consequences of the study. 
 
 
 
 
 
4.1 Human samples 
Table 3. Clinical characteristics of the patients. 
 
The study was approved by the Ethical 
Committee of Kuopio University Hospital, 
Kuopio, Finland and the study was in 
accordance with the principles outlined in the 
Declaration of Helsinki. 
   Both vitreous samples and neovascular 
tissues were collected from vitreoretinal 
surgeries. Vitreous humour was injected into 
a manually adjusted 2 ml aspiration syringe 
with infusion disconnected at the beginning 
of the pars plana vitrectomy. The sample was 
moved into a Eppendorf tube (Eppendorf 
Nordic, Horsholm, Denmark), and 
immediately stored in liquid nitrogen.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Later during the surgical procedure, a 
fibrovascular membrane was isolated from 
the surrounding vitreous and from the optic 
nerve head or retina, grasped with vitreous 
forceps and pulled out through a sclerotomy. 
The sample was placed in a 2.5 ml 
polypropylene tube (Meka Mini, Mekalasi 
Oy, Helsinki, Finland) in 4% PFA-sucrose, 
kept 1 h per 0.5 cm of neovascular tissue and 
embedded in paraffin for later 
immunohistochemical analyses.  
 
 
 
 
 
 
 
 
 
 
 Dm type 1 Dm type 2 Controls 
Number of 
patients 
13 17 7 
Age 
(years) 
34.7±8.8 60.4±8.4 71.6±4.5 
Duration of 
diabetes (years) 
24.2±5.9 17.5±8.4 - 
Gender 
(male/female) 
5/3 
62%/38% 
6/4 
53%/47% 
4/3 
57%/43% 
GHbA1c (%) 10.2±1.9% 9.1±1.9% - 
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4.2 Antibodies 
 
Table 4. Antibodies used in this study. 
 
 
 
 
 
 
Antibody Specificity Code/clone Species Dilutio
n 
Distributor Used  
CD-31 EC 
 
JC/70A mAb mouse anti-
human 
1:50 DAKO I-III 
PECAM-1 MEK13.3 mAb rat anti-mouse 1:50 BD  IV 
CD-68 Macrophages 
 
KP1 mAb mouse anti-
human 
1:50 DAKO I 
RAM11 RAM11 mAb mouse anti-rabbit 1:200 DAKO II-III 
mMQ AIA31240 pAb rabbit anti-mouse 1:5000 Accurate  IV 
VEGF-A VEGF-A sc-7269 mAb mouse anti-
human 
1:200 Santa Cruz  I-III 
VEGF-B VEGF-B sc-1878 pAb goat anti-human 1:200 Santa Cruz  I 
VEGF-C VEGF-C sc-1881 pAb goat anti-human 1:200 Santa Cruz  I 
VEGF-D VEGF-D 78923.11 mAb mouse anti-
human 
1:500 R&D  I,III 
PDGF-B PDGF-B  mAb mouse anti-
human 
1:100 R&D  I 
PlGF PlGF sc-1880 pAb goat anti-human 1:200 Santa Cruz  I 
anti-β-gal LacZ Z378 mAb mouse anti-β-gal 1:200 Promega II-III 
Ki-67 Proliferating cells 7B11 mAb mouse anti-
human 
1:100 Zymed  I 
HIF-1α  Hypoxia inducible  
factor  α  
H1α67 mAb mouse anti-
human 
1:100 Neomarkers I 
NFκB Nuclear factor κB 20 mAb mouse anti-
human 
1:250 BD  I 
αSMA α-smooth  
muscle actin 
1A4 mAb mouse anti-
human 
1:200 Sigma I-III 
ANG-1 Angiopoietin 1 sc-6319 pAb goat anti-human 1:100 Santa Cruz  I 
ANG-2 Angiopoietin 2 sc-7015 pAb goat anti-human 1:100 Santa Cruz  I 
Flt-1 VEGFR-1 sc-316 pAb rabbit anti-human 1:200 Santa Cruz  I 
KDR VEGFR-2 sc-6251 mAb mouse anti-
human 
1:200 Santa Cruz  I 
Flt-4 VEGFR-3 sc-321 pAb rabbit anti-human 1:200 Santa Cruz  I 
Tie-1 Angiopoietin  
receptor 1 
88016 mAb mouse anti-
human 
1:25 R&D  I 
Tie-2 Angiopoietin  
receptor 2 
83715 mAb mouse anti-
human 
1:25 R&D  I 
BrDU Proliferating cells Bu20a mAb mouse anti-
human 
1:100 DAKO II-III 
Caspase-3 Caspase-3 7481 pAb rabbit anti-human 1:250 Promega  IV 
Calbindin Calbindin D-28k CB38-a pAb rabbit anti-rat 1:1000 SWANT IV 
Calretinin Calretinin 7699/4 pAb rabbit anti-human 1:1000 SWANT IV 
anti-Rhodopsin Rhodopsin 9279 pAb rabbit  
anti-rhodopsin 
1:500 Chemicon IV 
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4.3 Gene transfer techniques 
Table 5. Animal models and viruses. 
 
 
 
 
Animal n Vector Promoter Transgenes Used 
in 
New Zealand White rabbit 43 Adeno 
serotype 5 
1st 
generation 
CMV hVEGF-A165 II 
hVEGF-D∆N∆C III 
KDR II 
LacZ II,III 
23 Baculo 
boost FGII-
B2  
hVEGF-D∆N∆C III 
GFP 
LacZ 
 
Animal Diet, n IV 
 Normal chow diet 
(R36, Lactamin, 
Sweden) for the whole 
time 
Western diet (TD 
88173, Harlan Teklad: 
42 % of calories from 
fat and 0.15 % from 
cholesterol, no sodium 
cholate) for the last 
three months 
IGF-II/LDLR–/–ApoB100/100 
mouse 
12 7 5 
LDLR–/–ApoB100/100 
mouse 
11 6 5 
 
All animal procedures were approved by 
Institutional Animal Care and Use Committee 
of the University of Kuopio, Kuopio, Finland. 
   Replication-deficient human clinical grade 
first generation adenoviruses (serotype 5) 
encoding transgenes under CMV promoter 
were constructed by homologous 
recombination, and produced in 293 cells 
(Laitinen et al., 1998; Rissanen et al., 2003). 
Adenoviruses were analyzed to be free of 
endotoxin and microbiological contaminants 
(Hedman et al., 2003). 
   Recombinant viruses encoding transgenes 
under CMV promoter were constructed using 
pFASTBac1-plasmid (Gibco BRL, Life 
Technologies, Gaithersburg, MD, USA) and 
a Bac-To-Bac Baculovirus Expression (Gibco 
BRL) system (Airenne et al., 2000). 
Baculoviruses were titered on Sf9 insect 
cells. Virus preparations were tested for 
sterility and analyzed for the absence of 
endotoxin and mycoplasma contaminations. 
In order to demonstrate that the virus 
preparations contained equal amounts of viral 
particles per volume, purified viruses (107 
pfu/lane) were subjected to immunoblotting 
using mouse anti-gp64 (Bioscience, San Jose, 
CA, USA) as a primary antibody and goat 
anti-mouse IgG-AP as a secondary antibody 
(Biorad Hercules, CA, USA). 
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Figure 10. Illustration of the gene transfer technique used in studies II-III. 
 
For the gene transfer, animals were 
anesthetized with subcutaneous injections of 
ketamin hydrochloride 0.3ml/kg (Ketalar, 
Pfizer, Espoo, Finland) and medetomidin 
hydrochloride 0.3ml/kg (Domitor, Espoo, 
Finland). Intravitreal injections were 
performed through pars plana 5mm from the 
limbus in the temporal side of the eye with a 
30G needle (BD Microlance, Drogheda, 
Ireland). The site of the needle tip was 
ensured with a microscope and the solution 
was injected into the vitreous humour. 
Oxybuprocain (Obucain, Santen, Tampere, 
Finland) was used for topical anesthesia. 
Animals were given cefuroxim 125mg 
(Zinacef, GlaxoSmithKline, Research 
Triangle Park, NC, USA) intramuscularly to 
avoid postoperative infections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45° 
0.1ml 
5mm 
30G 
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4.4 In vivo methods 
 
Table 6. In vivo methods used in this study. 
Method Description Distributor Used 
Anesthesia Ketamin 
hydrochloride 
0.3ml/kg (Ketalar) 
Intramuscular/ 
subcutaneous injection 
Pfizer, Espoo, Finland 
 
II-IV 
Medetomidin 
hydrochloride 
0.3ml/kg (Domitor) 
Intramuscular injection Orion, Espoo, Finland II-III 
Xylazine 10 mg/kg  
(Rompun) 
Subcutaneous injection Bayer  IV 
Topical 
drugs 
oxybuprocain 
(Obucain) 
  
Topical anesthesia  Santen, Tampere, 
Finland 
II-IV 
Tropicamid 5mg/ml 
and Phenylephrine 
hydrochloride 
100mg/ml 
 
Mydriasis II-IV 
Photographs Anterior and posterior 
parts of the eye  
Zeiss, FF450 PLUS IR, 
Jena, Germany;  
Canon, CF-60UVi, 
Latham & Phillips 
Ophthalmic Products, 
Grove City, Ohio, USA 
II-III 
Nikon D70s, Nikon 
Corp., Tokyo, Japan 
IV 
FAG 0.3 ml of 
Fluorescein Sodium (AK-
FLUOR 10%)  
 
Intravenous injection, 
evaluation of the fundus 
in 2min time period 
Akorn, Buffalo Grove, 
IL, USA 
III 
Biomicroscopy Evaluation of of the eye   Haag-Streit, Bern, 
Switzerland 
II-IV 
Metabolic 
analyses 
Blood glucose Overnight fasting plasma 
samples 
Glucometer Elite 
analyzer , Bayer 
IV 
Plasma insulin levels Rat/mouse Insulin 
ELISA Kit, Linco 
Research Inc. 
Triglycerides  Ecoline S+, GPO-PAP 
method, Diagnostic 
Systems  
Total cholesterol Ecoline 25, CHOD-
PAP method, Merck 
Diagnostica  
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4.5 Analytical methods 
Table 7. Analytical methods used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Method Description Distributor Used  
Tissue 
processing 
Fixation Embedding Sectioning  I-IV 
 Paraffin blocks 
 
4% PFA 
for 5 h 
paraffin 
 
4-7 µm 
sections  
Frozen sections 
 
x-gal fix 33% optimal cutting 
temperature (OCT) 
compound 
 
Sakura 
Finetek, 
Zoeterwoude, 
the 
Netherlands 
II-III 
Flat mount 4% PFA for 1 h IV 
Liquid nitrogen Vitreous samples (0.3–0.4 mL) from each eye  
with a 1 mL syringe and a 24 G needle 
 
I-III 
Immunology  Immunohisto- 
chemistry 
Paraffin-embedded samples  I-IV 
ELISA, 
Quantikine 
Assays with vitreous 
samples 
R&D Systems, Minneapolis, MN, 
USA 
I-III 
Histological 
analyses 
Olympus AX70 Photographs and 
analyses of the 
histological sections 
Olympus Optical, Tokyo, Japan I-IV 
AnalySIS  GmBH, Munster, Germany 
PhotoShop  
 
Adobe, San Jose, CA, USA 
Other 
methods 
Fluorescence microscopy for GFP 
expression  
ECLIPSE E600, Nikon, Japan III 
Retina flat 
mounts 
4% PFA for 10 min. The 
cornea, lens, sclera, and 
vitreous excised and the 
retina isolated. Retina flat 
mounts fixed with 4% PFA 
for 1 hour 
Confocal 
microscopy 
Olympus IX70,  
Perkin Elmer 
IV 
Fluorescence 
conjugated 
isolectin 
GS lectin, I-
21413;  
Molecular Probes 
Statistical 
analyses 
mean± SEM or SD I-IV 
 
 
one-way ANOVA 
independent samples t-test 
Kruskal-Wallis test 
Mann-Whitney U-test 
Spearman’s correlation analysis I 
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5 RESULTS 
 
 
5.1 Angiogenic factors in vitreous humour and neovascular samples in type 1 and type 2 
diabetic retinopathy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Scatter Plot analysis of type 1 and type 2 diabetic patients with proliferative 
retinopathy. (A) Correlation between the number of CD-31 positive endothelial cells in the 
tissue/mm2 and ANG-2 in vitreous humour (p<0.05). (B) Correlation between ANG-2 and 
VEGF-A in vitreous humour (p<0.01). 
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VEGF-A, ANG-1 and ANG-2 were found in 
the vitreous samples in both types of 
diabetics but there was no difference between 
type 1 and type 2 diabetics in ELISA analysis 
in the amounts of measured growth factors. 
In addition, ANG-1 was found in much lower 
levels than VEGF-A or ANG-2.  
The number of capillaries correlated 
positively with the amount of ANG-2 in the 
vitreous humour in type 1 (p < 0.05, r = 0.77) 
but not with type 2 diabetics. ANG-2 and 
VEGF-A in the vitreous humour correlated 
positively (p < 0.01, r = 0.59) with type 2 
diabetics (Figure 11). 
   Numerous CD31-positive ECs and several 
CD68 positive macrophages were present in 
all neovascular samples. In type 1 diabetics, 
the number of ECs in fibrovascular tufts was 
significantly higher than in type 2 diabetics (p 
< 0.05). α-SMA positive pericytes were 
found in the neovascular tufts in the same 
areas as ECs, but the number of ECs was 
higher than activated pericytes in the tissues. 
   Transcription factor NFκB, which mediates 
inflammatory responses, was also present in 
the nuclei in the samples of all patients 
indicating an ongoing inflammatory process 
in the neovascular tissues. A positive staining 
for Ki-67 indicates a proliferative process in 
the tufts in all patients. Almost every sample 
had HIF-1α stained nuclei reflecting hypoxic 
conditions in the eye. There were no 
differences in inflammatory response, 
number of proliferating cells, 
immunostaining for HIF-1α or α-SMA 
stainings between type 1 and type 2 diabetics.  
   Duration of diabetes correlated positively 
with the age of the patient (p < 0.05) but had 
no effect on the number of ECs neither in 
type 1 nor type 2 diabetics. The number of 
ECs and age had a significant negative 
correlation (p < 0.05, r = -0.74) in type 1 
diabetics. GHbA1c levels (p < 0.01, r = 0.58) 
had a positive correlation with the number of 
ECs in type 1 but not in type 2 diabetics 
(Figure 12). 
   All studied growth factors were found in 
the endothelial cells in neovascular tufts. 
There were staining differences in the 
presence of growth factors in the neovascular 
tufts between type 1 and type 2 diabetics. In 
type 1 diabetics, VEGF-A was most strongly 
present whereas over 50% of type 2 diabetics 
had either equal or more intense staining for 
VEGF-D than VEGF-A. ANG-2 were less 
abundant than VEGF-A or VEGF-D, but 
more abundant than the other measured 
factors. The overall order of the growth 
factors was VEGF-A > ANG-2 > VEGF-D, 
ANG-1 > VEGF-C > VEGF-B, PlGF > 
PDGF-B in type 1 diabetics and VEGF-D, 
VEGF-A > ANG-2 > ANG-1 > PLGF > 
VEGF-B > VEGF-C > PDGF-B in type 2 
diabetics. 
   In type 1 diabetics, VEGF-C was more 
abundant than VEGF-B, and in type 2 
diabetics, the situation was opposite. The 
presence of all VEGF receptors was 
significantly higher in type 1 diabetics than in 
type 2 diabetics (p < 0.05) (Figure 13). In 
addition, VEGFR-1 and VEGFR-3 were 
stronger than VEGFR-2 particularly in type 2 
diabetics. Presence and location of PDGF-B, 
ANG-1, ANG-2, Tie-1 and Tie-2 in type 1 
diabetics were similar to type 2 diabetics. 
ANG-1 and ANG-2 and their receptors Tie-1 
and Tie-2 were mostly present in the same 
areas as pericytes. Immunostaining for 
PDGF-B was less abundant than VEGFs. 
VEGF-A and VEGFR-1 were also present in 
the control samples but much less abundantly 
than in the diabetic tissues. ECs and α-SMA 
positive pericytes were also present in non-
diabetic eyes but in much less numbers than 
in diabetic fibrovascular tissues. There were 
no NFκB, Ki-67 or HIF-1α positive cells in 
the control retinas. 
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Figure 12. Scatter Plot analysis of type 1 and type 2 diabetic patients with proliferative 
retinopathy. (A) Correlation between the number of CD-31 positive endothelial cells/mm2 and 
age of patients (p<0.05). (B) Correlation between the number of CD-31 positive endothelial 
cells/mm2 and glycosylated haemoglobin (GHbA1c, %) (p<0.01).  
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Figure 13. Vascular endothelial growth factors and their receptors in type 1 and type 2 diabetic 
retinopathy. 
 
 
Figure 14. Capillary area in the retina after adenoviral and baculoviral intravitreal gene transfer 
encoding VEGF-A165 and VEGF–D∆N∆C. 
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5.2 Intravitreous VEGF-A165 and VEGF-D 
∆N∆C
 gene transfer 
5.2.1 Dose–response studies 
The amount of human VEGF-A165 and 
VEGF-D∆N∆C in the vitreous humour showed 
a dose-dependent increase with the virus dose 
in the vitreous humour after intravitreous 
injection.  
   In the 108 IU/ml eyes, there was no 
significant difference in the amount of human 
VEGF-A165 or VEGF-D∆N∆C in vitreous 
humour when compared to control eyes. 
However, in the vascular structures a 
significant dilation and tortuosity of the 
vessels were seen in postoperative 
photographs and in the histological analyses 
6 days after the gene transfer with both 
growth factors. The difference in capillary 
area between VEGF-A165 and VEGF-D∆N∆C 
gene transfer was significant (p < 0.05) 
(Figure 14).  
   In the 109 IU/ml eyes, clear changes were 
observed in the photographs taken after gene 
transfer. Moreover, the amount of human 
VEGF-A165 or VEGF-D∆N∆C in vitreous 
humour was significantly higher (p < 0.05) 
than in control eyes. Haemorrhages and 
microaneurysms were present near the optic 
disc. The optic nerve head was swollen 
indicating an increased permeability of the 
retinal vessels and breakdown of the blood-
retina barrier. Retinal vessels were dilated 
and tortuous. Hyperaemia was seen in the 
anterior segments in the conjunctiva and the 
iris. Histological analyses revealed a 
significant difference (p < 0.05) between 
VEGF-A or VEGF-D∆N∆C 109 IU/ml eyes and 
control eyes in the average capillary area. 
Furthemore, VEGF-A165 transduced eyes had 
a significantly higher average capillary area 
than VEGF-D∆N∆C transduced eyes (p<0.05) 
(Figure 14). 
    In the VEGF-A165 5x109 IU/ml eyes, new 
vessels were seen in post-operative fundus 
photographs. In histological analyses, there 
were lots of new vessels both in the anterior 
segments and the retina.  
   A strong inflammatory reaction was seen in 
the VEGF-A165 and VEGF-D∆N∆C 1010 IU/ml 
transduced eyes. The fundus was not clearly 
visible any more due to the leaky retinal 
vessels. After VEGF-A165 1010 IU/ml gene 
transfer, anterior segments were strongly 
hyperaemic and chemotic and the cornea was 
swollen and clouded. Also in histologic 
analysis anterior segments and normally 
avascular cornea were full of sprouting 
fragile new vessels. Microvascular density in 
the anterior segments of the VEGF-A165 1010 
IU/ml eyes was much higher than with other 
doses. In the AdVEGF-A165/AdsKDR 
combination group, no new changes were 
seen in the vasculature in the fundus 
photographs or in histologic analyses 
confirming the significant role of VEGF-A165 
in the pathogenesis of ocular 
neovascularization.  
   Also VEGF-D∆N∆C 1010 IU/ml caused an 
increase in the number of enlarged capillaries 
in the retina and optic nerve head (p<0.05) 
when compared to the control eyes. However, 
the difference in capillary area after VEGF-
A165 and VEGF-D∆N∆C gene transfer was 
significant (p < 0.05) (Figure 14). 
 
5.2.2 Time curve of the effects of 
adenoviral VEGF-A165 or baculoviral 
VEGF-D∆N∆C gene transfer 
The amount of human VEGF-A165 in the 
vitreous humour was significantly increased 
(p < 0.05) 3 days after the adenoviral VEGF-
A165 gene transfer when compared to AdLacZ 
injection (Figure 15). However, only slight 
changes were found in the vasculature of the 
eye in fundus photographs or in histological 
analyses. 
   The amount of human VEGF-A in the 
ELISA assay in vitreous humour was highest 
6 days after the gene transfer (Figure 15). In 
fundus photographs 6 days after the 
AdVEGF-A165 injection blood vessels were 
swollen, leaky and tortuous. Hyperaemia was 
present in the anterior segments. In 
histological analyses, a clear response to the 
AdVEGF-A165 gene transfer was found 
especially in the retina and the optic nerve 
head. The increase in the average capillary 
area in the AdVEGF-A165 109 IU/ml eyes 
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compared with the AdLacZ 109 IU/ml eyes 
was significant in the retina, the optic nerve 
head and the anterior segments (p < 0.05). 
Microvascular density was increased in the 
retina and the optic nerve head but not in the 
anterior segments.  
   Two weeks after the gene transfer, the 
amount of human VEGF-A165 in the vitreous 
humour had decreased (Figure 15). Vitreous 
haemorrhages were present in fundus 
photographs and it was very difficult to 
evaluate retinal vessels. The anterior parts 
were still slightly hyperaemic. In histological 
analyses, the response to the AdVEGF-A165 
gene transfer was as strong as 6 days after the 
gene transfer in the retina and the optic nerve 
head and even stronger in the anterior 
segments. Microvascular density was 
increased in the retina, the anterior segments 
and the optic nerve head. The number of 
proliferating cells was at its highest 2 weeks 
after the gene transfer especially in the 
anterior segments. 
   Four weeks after the gene transfer, no 
human VEGF-A165 was found in the vitreous 
humour (Figure 15). The anterior parts had 
returned to normal. In fundus photographs, 
haemorrhages were resolved and fibrous 
scars were seen just above the optic nerve 
head. There were no changes in the control 
AdLacZ eyes. In histological analyses, there 
were no significant differences in the average 
capillary area in the anterior segments when 
compared to the AdLacZ 109 IU/ml eyes. 
However, in the optic nerve head and 
especially in the retina the difference was still 
significant (p < 0.05). Microvascular density 
in the retina and in the anterior segments was 
also increased. Double immunostaining with 
CD31 and alpha-actin revealed vessels with 
abnormal pericytes and vessels containing 
only ECs. The number of macrophages in 
RAM-11 staining was at its highest four 
weeks after the AdVEGF-A165 gene transfer.  
   The highest baculovirus-mediated VEGF-
D∆N∆C expression in the vitreous humour was 
detected at 3 days after the intravitreal 
administration (Figure 15). Haemorrhages 
were seen near the optic nerve head both in 
the BacVEGF-D∆N∆C transduced eyes and in 
the BacLacZ control eyes. Furthermore, in 
the BacVEGF-D∆N∆C treated eyes capillaries 
were slightly dilated and the capillary density 
was significantly increased in the optic nerve 
head and in the anterior segments compared 
to the BacLacZ eyes (p < 0.05). However, 
there was no significant difference between 
BacVEGF-D∆N∆C and BacLacZ treated eyes 
in the dilatation of retinal vessels. Only a few 
macrophages were found both in the 
BacVEGF-D∆N∆C and BacLacZ treated eyes.  
   At 6 days after the BacVEGF-D∆N∆C 
intravitreal injection the amount of VEGF-
D∆N∆C in the vitreous humour had diminished 
by half (Figure 15). The fundus was not 
clearly visible because of the breakdown of 
the blood retina barrier. There was an 
increased number of enlarged capillaries in 
the retina and optic nerve head (p < 0.05) in 
the BacVEGF-D∆N∆C eyes when compared to 
the control eyes. The number of RAM-11-
immunopositive macrophages was 
significantly higher in the BacVEGF-D∆N∆C 
treated eyes at 6 days after intravitreal 
injection than at 3 days (p < 0.05). 
   Two weeks after the intravitreal injection, a 
40-fold drop was detected in the amount of 
VEGF-D∆N∆C in vitreous humour compared 
to the highest level at 3 days (Figure 15). 
Both BacVEGF-D∆N∆C and BacLacZ eyes 
were calm and the fundus area was 
normalized. The capillaries in the optic nerve 
head and in the retina looked diminished and 
the number of RAM-11-immunoreactive 
macrophages was lower when compared to 
eyes of rabbits that were treated for 6 days. 
   The lowest level of VEGF-D∆N∆C 
expression was found in the 4-week treatment 
group (Figure 15). Four weeks after the 
intravitreal injection the eyes were calm. No 
leakages were found in the retinal vessels in 
FAG. Capillaries were not dilated and the 
average capillary area was not increased 
when compared to the control eyes. However, 
the number of RAM-11-immunoreactive cells 
in the transduced eyes was similar to that 
seen in the two weeks group. 
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Figure 15. Time curve for adenoviral and baculoviral gene transfer. 
 
5.3 Assessment of Baculoviral and 
Adenoviral Gene Transfer 
The efficiency of baculo- and adenovirus-
mediated gene transfer was directly assessed 
by examination of GFP-positive or LacZ-
positive cell layers in the anterior and 
posterior parts of the eye. Baculoviral 
transfection was highly efficient for 
photoreceptor cells and RPE, and to a lesser 
extent for the inner retina. Adenoviral gene 
expression was detected mostly in the 
anterior segments, especially in the iris and 
the ciliary body, in the NFL and GCL of the 
retina. Also VEGF-D∆N∆C expression showed 
similar pattern in the retina and RPE layer 
after baculoviral and adenoviral transduction 
(Figure 16). Adenovirus mediated expression 
of VEGF-D∆N∆C in the vitreous humour was 
significantly higher than that of baculovirus 
at 109 and 1010 IU/ml. Both BacVEGF-D∆N∆C 
and AdVEGF-D∆N∆C caused dilatation of 
capillaries in all parts of the eye already at a 
dose of 108 IU/ml (p < 0.05). Both 
baculoviral and adenoviral gene transfers 
caused similar inflammatory response: 
macrophage invasion into the anterior 
segments, the retina and the optic nerve head 
of the eye. Inflammation-like alterations in 
the choriocapillaries were observed in 
BacVEGF-D∆N∆C treated eyes, but not in 
AdVEGF-D∆N∆C treated ones at 6 days after 
the gene transfer. 
 
 
Figure 16. VEGF-D∆N∆C expression in the 
retina and RPE layer after baculoviral (A, C) 
and adenoviral (B, D) transduction. Scale bar 
= 20 µm. 
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5.4 IGF-II/LDLR–/–ApoB100/100 mouse  
Fasting glucose levels of 15-month-old 
diabetic IGF-II/LDLR-/-ApoB100/100 mice 
were significantly elevated on Western diet 
compared to LDLR-/-ApoB100/100 controls 
(8.2±2.1 versus 4.6±1.1 mmol/L, P<0.05), 
but with normal diet, there was no significant 
difference in glucose values between diabetic 
and control animals.  In vivo examination of 
the mice eyes in biomicroscopy revealed no 
significant changes in neither diabetic 
animals fed with normal or Western diet nor 
in controls.  The pupils dilated normally with 
mydriatics and retinal photographs of the 
mice revealed no clinical diabetic changes in 
the retinas neither in the diabetic nor in the 
control animals. The number of capillaries in 
IGF-II/LDLR–/–ApoB100/100 mice was not 
significantly increased compared to control 
LDLR–/–ApoB100/100 mice. The number of 
pericytes did not differ between the diabetic 
and control animals. Capillaries were 
similarly situated in the nerve fiber layer and 
in the outer plexiform layer and there were no 
haemorrhages or other signs of 
hyperpermeability of the vessels in the retinal 
layers. In paraffin embedded samples stained 
with haematoxylin-eosin, the altered 
morphology of the entire retina was found in 
all IGF-II/LDLR–/–ApoB100/100 mice fed with 
normal diet. There were displaced amacrine 
cells in the inner plexiform layer which 
stained positively with calbindin, a specific 
marker for amacrine cells. The morphology 
of the inner nuclear, outer plexiform and 
outer nuclear layers was abundantly altered in 
the diabetic IGF-II/LDLR–/–ApoB100/100mice. 
Photoreceptor atrophy and thinning of the 
outer nuclear layer with large acellular areas 
were also present (Figure 17). There were no 
differences between the control and the 
diabetic mice in the retinal expression of heat 
shock proteins. However, caspase-3 was 
abundantly positive in the inner segment of 
photoreceptor cells indicating mitochondrial 
oxidative stress in the IGF-II/LDLR-/-
ApoB100/100 mice. No such staining was 
observed in their littermate LDLR–/–
ApoB100/100 controls. To evaluate the retinal 
structure of diabetic IGF-II/LDLR–/–
ApoB100/100 mice, rhodopsin, a 
transmembrane protein that initiates the 
visual transduction cascade was studied with 
antibody against rhodopsin. Rhodopsin 
staining was reduced in the retinas of diabetic 
animals, consistent with the decreased 
number of photoreceptor cells.  
 
 
 
 
 
 
 
 
 
 
Figure 17. Haematoxylin-eosin stained 
samples show displaced cells and altered 
morphology throughout the retina of IGF-
II/LDLR-/-ApoB100/100 mice fed with normal 
diet (large arrows; A, B). Photoreceptor 
atrophy is also present (arrowhead; B). 
Control animals have normal retinal 
morphology (C).  
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5.5 Summary of findings in this study 
 
Study Model Conclusions 
I Growth factor expression 
in diabetic retinopathy 
Different growth factor patterns 
between type 1 and type 2 
diabetic proliferative 
retinopathy 
II Adenoviral VEGF-A165 
gene transfer in the 
vitreous humour  
Adenovirally delivered VEGF-
A165 causes neovascularization 
in the retina and in the anterior 
segments 
III Baculoviral VEGF-D∆N∆C 
gene transfer in the 
vitreous humour  
Baculoviral gene transfer is 
efficient in transducing 
photoreceptor layer and RPE 
VEGF-D∆N∆C causes blood 
retina barrier breakdown but no 
neovascularization in the eye 
IV Ocular findings of 
diabetic IGF-II/LDLR–/–
ApoB100/100 mice 
Diabetic IGF-II/LDLR–/–
ApoB100/100 mice reveal 
photoreceptor atrophy and 
altered retinal morphology 
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6 DISCUSSION 
 
6.1 Angiogenic factors in diabetic 
retinopathy 
Several angiogenic factors and their receptors 
are found in the neovascular tissue and in 
vitreous humour in diabetic retinopathy. 
VEGF-A and ANG-2 were equally abundant 
in the vitreous humour of studied diabetics. 
The amount of VEGF-A in the vitreous 
humour was at the same level as in previous 
studies, and also increased ANG-2 levels 
have been found in the vitreous humour of 
diabetic patients (Aiello et al., 1994; 
Watanabe et al., 2005).  ANG-2 expression 
has been demonstrated at the outer border of 
the inner nuclear layer, which is in close 
proximity to the deep retinal capillaries. The 
localized production of ANG-2 in the region 
of the deep capillaries may be the reason for 
their increased sensitivity to VEGF (Hackett 
et al., 2000).  ANG-2 deficient mice develop 
abnormal retinal vascular bed consisting of 
some formation of the superficial capillaries, 
but display an almost complete lack of vessel 
penetration into the retina resulting in the 
absence of the intermediate and deep 
capillary plexus. In addition, ANG-2 
deficient mice fail to develop ischemia-
induced retinal neovascularization (Hackett et 
al., 2002).  Furthermore, inhibition of Tie-2, 
when combined with inhibition of VEGF, 
suppresses retinal angiogenesis more 
efficiently than inhibition of VEGF alone, 
suggesting that signaling of both Tie-2 and 
VEGF plays a potential role in ischemia-
induced retinal angiogenesis (Takagi et al., 
2003). ANG-2 and its signaling pathways 
provide new molecular targets for the 
development of new treatments for ocular 
neovascularization. 
   In our study, type 1 diabetics had much 
more VEGF-A in the samples than other 
measured growth factors. In type 2 diabetics, 
VEGF-D was equally or even more 
abundantly present than VEGF-A in the 
neovascular tissues in more than 50% of the 
patients. VEGF-C was more abundantly 
present than VEGF-B in the neovascular 
tissues in type 1 diabetics. With type 2 
diabetics, the situation was opposite. VEGF-
A, VEGF-C and VEGF-D angiogenic effects 
are mediated by VEGFR-2. VEGF-A and 
VEGF-B signal through VEGFR-1. In 
addition, VEGFR-3 mediates the actions of 
VEGF-C and VEGF-D. VEGFR-2 is usually 
seen as the most important mediator of blood 
vessel growth. Signalling of VEGF-A by 
VEGFR-2 is fast and transient whereas 
signalling of VEGF-D is slower and more 
long-lasting (Jia et al., 2004).  VEGFR-3 is 
mainly expressed on lymphatic endothelium 
and VEGF-C and -D are thought to play a 
role in the maintenance of lymphatic 
endothelium and in lymphangiogenesis (Iljin 
et al., 2001; Stacker et al., 2001).  However, 
they have also been found in vascular 
structures (Rutanen et al., 2003; Witmer et 
al., 2001; Zhao et al., 2007).  Expression of 
VEGFR-3 has been found particularly in 
areas with leaky retinal microvessels (Witmer 
et al., 2002). In the present study we found 
more immunoreactive VEGFR-1 and 
VEGFR-3 than VEGFR-2 in the neovascular 
tufts in both types of diabetics suggesting the 
important role of these receptors in the 
pathogenesis of diabetic retinopathy and in 
the formation and maintenance of 
microvessels such as retinal capillaries. 
VEGF-B mRNA is expressed in the 
developing retina (Simpson et al., 1999; 
Yonekura et al., 1999).  However, VEGF-B 
expression appears not to be up-regulated in 
hypoxia, and the physiological role of VEGF-
B remains essentially unknown (Gollmer et 
al., 2000).  In addition, VEGF-B is unlikely 
to be necessary for the development of the 
retinal vasculature in an animal model under 
normal conditions (Reichelt et al., 2003).  
Recent reports have shown that VEGFR-1, 
mediator for action of VEGF-B, is also found 
in non-vascular retinal tissues in the mouse 
and primate eye (Robinson et al., 2001; 
Witmer et al., 2002).  The fact that neural 
retina is also damaged in diabetic retinopathy 
may explain the existence of VEGF-B in 
diabetic neovascular tissues.  
   Our finding showing VEGF-C expression 
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in proliferative diabetic retinopathy is in line 
with a recent study of Zhao and coworkers 
(Zhao et al., 2007). In addition, VEGF-C is 
shown to be regulated by both VEGF-A and 
high glucose and promote angiogenesis in 
vitro enhanced by the presence of VEGF-A 
(Zhao et al., 2006).  VEGF-D was not found 
in the vitreous humour in any patient in this 
study indicating that VEGF-D binds to retinal 
tissues more efficiently than the other growth 
factors in diabetic patients. VEGF-D has also 
recently been found in the subretinal vascular 
membranes of patients with AMD suggesting 
that it also plays some role in the 
pathogenesis of choroideal angiogenesis 
(Ikeda et al., 2006).  It has been shown that 
cell–cell adhesion and cell attachment 
independently regulate the VEGF-D mRNA 
expression in human RPE in vitro suggesting 
that the breakdown of these interactions 
causes the overexpression of VEGF-D (Ikeda 
et al., 2006).   
   The difference in growth factor and growth 
factor receptor expression in the retinas 
between type 1 and type 2 diabetics might 
contribute to the differences in their 
pathogenesis and clinical course. Type 1 
diabetics have a much higher risk of 
developing proliferative retinopathy than type 
2 diabetics and in type 2 diabetics, diabetic 
maculopathy is the most prevalent sight-
threatening manifestation of retinopathy 
(Henricsson et al., 1996; Klein et al., 1984). 
In the pathogenesis of vascular diseases in 
type 2 diabetes, the damage and dysfunction 
of endothelial cells have shown to play a 
crucial role (Tooke, 2000). Similarly to 
studies in RPE cells, VEGF-D may contribute 
to the    breakdown of the inner blood retina 
barrier in diabetic patients leading to 
maculopathy and oedema in type 2 diabetics.  
Macrophages secrete many angiogenic and 
lymphangiogenic factors, including VEGF-D 
(Cursiefen et al., 2004).     Inflammation has 
shown to be involved in many ocular 
neovacular diseases (Killingsworth et al., 
1990; Meleth et al., 2005). Although the 
precise role of inflammation in the 
development of diabetic retinopathy is still 
unclear, it is possible that inflammatory 
mechanisms accelerate proliferative 
retinopathy in type 2 diabetics by VEGF-D 
dependent pathways. On the other hand, the 
fact that type 1 diabetics had more VEGF-A 
in the neovascular tissues than VEGF-D, 
suggests that with type 1 diabetics, hypoxia is 
more important in the development of 
proliferative retinopathy than inflammation. 
In order to stop the proliferative process, it 
might also be beneficial to prevent 
inflammation in the eye especially in type 2 
diabetics.     
   HIF-1α is activated in hypoxic conditions 
preceding the development of various 
retinopathies and stimulates the expression of 
proangiogenic growth factors (Semenza and 
Wang, 1992; Wiesener et al., 1998). HIF-1α 
has been found in the epiretinal membranes 
of diabetic patients without previous laser 
photocoagulation (Abu El-Asrar et al., 2007).  
It was also demonstrated that HIF-1 mediates 
the hypoxic upregulation of VEGF and ANG-
2 in vascular ECs (Yamakawa et al., 2003).  
Hyperglycemia can also regulate HIF-1α 
protein stability by interfering with its 
proteosomal degradation (Catrina et al., 
2004).  Also in this study, HIF-1α was 
detected both in type 1 and type 2 diabetic 
eyes despite of the previous panretinal laser 
photocoagulation. Normally, the retinal 
vessels are autoregulated in hypoxic 
conditions. However, the pathologic changes 
in retinal vasculature in diabetic retinopathy 
cause the distraction of the normal 
autoregulatory mechanism leading to active 
angiogenic process and proliferation. 
Manipulation of the HIF-1α pathway in the 
treatment of diabetic retina might be an 
attractive choice in addition to targeting 
VEGF and other growth factors.   
   Nuclear factor κ B (NFκB) is an ubiquitous 
transcription factor that, by regulating the 
expression of multiple inflammatory and 
immune genes, plays a critical role in host 
defense and in chronic inflammatory diseases 
(Barnes, 1997). NFκB is activated under 
hypoxic conditions, in retinal ECs or 
pericytes exposed to elevated glucose 
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concentration and in retinas of diabetic rats 
(Cummins and Taylor, 2005; Kowluru et al., 
2003; Zheng et al., 2004; Zheng et al., 2004).  
Specific NFκB inhibitors were able to inhibit 
cell death in vitro and suppress retinal 
neovascularization in an OIR mouse model 
(Yoshida et al., 1999; Zheng et al., 2004).  It 
has also been demonstrated that VEGF is able 
to activate NFκB in ECs (Grosjean et al., 
2006).  In previous studies, elevated levels of 
NFκB, chemokines and cell adhesion 
molecules have been identified in the eyes 
with proliferative diabetic retinopathy 
(Harada et al., 2006; Meleth et al., 2005).  In 
this study, macrophages and NFκB were 
abundantly present in the neovascular 
samples in both types of diabetes. In diabetic 
rats, non-steroidal salicylate-based anti-
inflammatory drugs have been shown to 
significantly inhibit the degeneration of 
retinal capillaries and prevent ganglion cell 
loss. The salicylate-mediated inhibition of 
early stages of diabetic retinopathy is due at 
least in part to inhibition of the diabetes-
induced activation of NFκB and other 
transcription factors in the retina (Zheng et 
al., 2007).     
   All patients in our study had had previous 
panretinal laserphotocoagulation because of 
the proliferative retinopathy and in this sense, 
groups of type 1 and type 2 diabetic patients 
are comparable. The quantity of retinal 
photocoagulation was on average 1125 
applications in type 1 and 1660 applications 
in type 2 diabetics. The mean time scale of 
laserphotocoagulation before vitrectomy was 
on average 8 months in type 1 diabetics and 
16 months in type 2 diabetics. Laser 
photocoagulation has been shown to 
upregulate the expression of VEGF and 
transcription factors in photocoagulated 
human RPE cells in vitro 6 hours after 
photocoagulation. 72 hours after 
photocoagulation the expression of VEGF 
was decreased to the level before 
photocoagulation (Ogata et al., 2001b). In an 
in vivo study, changes in growth factor 
expression following laser photocoagulation 
were observed only in    burn areas and 
mainly confined to the RPE and outer nuclear 
layer. The immunoreactivity was increased 
within the outer nuclear layer of burn areas 
during the healing process but returned to 
normal by 42 days (Xiao et al., 1999). Based 
on these reports it is presumable that the laser 
photocoagulation causes only temporal 
increase on growth factor expression. 
6.2 Antiangiogenic strategies 
With the current anti-VEGF treatment the 
ocular neovascular diseases are not cured, the 
progression of the disease is just slowed 
down. Current therapies to inhibit 
pathological angiogenesis in the eye use 
mostly inhibitors of one or two growth 
factors. This strategy has had only limited 
success (Afzal et al., 2007). This might be 
explained by other angiogenic factors 
involved that are not affected by the anti-
VEGF agents. Potential future approaches to 
pathological angiogenesis could be based on 
angiogenesis inhibitors that simultaneously 
target several angiogenic factors or on 
blocking some master modulators such as 
HIF-1α. However, it must be remembered 
that angiogenic growth factors also have 
important roles and protective properties in 
the normal eye and blocking the action of 
VEGF completely can be harmful in the long 
run.  
   Most of the existing angiogenic inhibitors 
are large proteins or peptides. There is 
currently no effective drug delivery route for 
the administration of these agents into the 
most susceptible sites for ocular NV, the 
retina and the choroid. With systemic 
administration the drug is not able to 
efficiently reach the retina and choroid 
because of the blood retina barrier. In 
addition, many diseases involving ocular 
neovascularization are chronic disorders 
which require a long-term administration of 
drugs. Recent angiogenic inhibitors have a 
relatively short half-live, which means these 
agents need to be injected repeatedly (Cao, 
2001). Furthermore, most of the angiogenic 
inhibitors are effective only in preventing the 
development of ocular neovascularization 
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(Das and McGuire, 2003; Zhang et al., 2001). 
Clinically, most ocular neovessels are formed 
in an indefinite period. Therefore, the 
angiogenic inhibitors regressing existing 
ocular neovascularization would be more 
useful in the treatment of ocular neovascular 
diseases.  
6.3 VEGF-A and VEGF-D in a rabbit 
model 
Type 1 diabetic patients had abundant VEGF-
A in the samples. In type 2 diabetic patients, 
VEGF-D was equally or even more 
abundantly present than VEGF-A. Based on 
these results, following studies with rabbits 
were focused on VEGF-A and VEGF-D 
effects in ocular tissues. In addition, we 
wanted to explore adenovirus and baculovirus 
as gene transfer vectors for more sustained 
therapy for ocular angiogenesis compared to 
current treatment.   Adenovirally delivered 
intravitreous VEGF-A165 caused increased 
dilation, tortuosity and leakage of the retinal 
vessels, breakdown of the blood-retina barrier 
and dilation of the capillaries in the optic 
nerve head and the anterior segments 
resembling the changes of diabetic 
retinopathy. Long lasting hyperglycaemia 
causes microvascular damage leading to 
pericyte loss, basement membrane 
thickening, microaneurysm formation and 
capillary hypoperfusion resulting in hypoxia 
and ischaemia (Garner, 1994). In healthy 
monkey eyes, intravitreal injection of VEGF 
caused retinal capillary nonperfusion 
documented by  FAG. This might be 
explained   by EC hyperplasia and 
subdivision or complete obstruction of vessel 
lumen by dividing ECs (Tolentino et al., 
2002). Ischaemia leads to overexpression of 
VEGF-A  which promotes neovascularization 
(Ozaki et al., 1997; Yla-Herttuala and Alitalo, 
2003). In our present study, high doses and/or 
long follow-up VEGF-A165 caused 
neovascularization in the anterior segments, 
the retina and the optic nerve head, whereas 
the choroidal vessels remained unchanged. 
The changes were   blocked by soluble KDR, 
which confirms the significant role of VEGF-
A165 and VEGFR-2 in causing these effects. 
Overexpression of VEGF-A in the RPE is 
shown to induce vascular leakage, new 
choroidal blood vessel growth, the 
development of CNV and neural retina 
degeneration (Spilsbury et al., 2000).  The 
development of CNV requires VEGF to be 
secreted from the RPE toward the inner 
choroid where high levels of VEGF receptors 
have been found (Blaauwgeers et al., 1999).  
Transgenic mice expressing VEGF in 
photoreceptor cells develop subretinal 
neovascularization of retinal vasculature 
origin and not from the choroid (Okamoto et 
al., 1997; Tobe et al., 1998a). VEGF 
expressed by the photoreceptor cells may be 
unable to pass through the outer blood-retina 
barrier to exert any effect on the choroid 
(Tobe et al., 1998a).      
   VEGF-D∆N∆C caused a dose-dependent 
enlargement of capillaries and break down of 
the blood-retina barrier. However, intravitreal 
injection of VEGF-D∆N∆C was not capable of 
inducing neovessel formation in the eye 
although other effects were similar to VEGF-
A. VEGF-D∆N∆C in vitro leads to an 
approximately 2-fold greater increase in the 
number of bovine aortic endothelial cells 
after 3 days compared to the control. 
However, this effect is approximately 5-fold 
less potent than VEGF165 (Achen et al., 
1998).   
6.4 Diabetic mouse model 
The progression of diabetic retinopathy has 
not undeniably shown to correlate with 
dyslipidemia (Kohner et al., 1998; Stratton et 
al., 2001). The plasma lipid levels did not 
differ between diabetic IGF-II/LDLR–/–
ApoB100/100 and control LDLR–/–ApoB100/100 
mice on neither of the diets. Therefore, the 
alterations in the retinal morphology are not 
caused by dyslipidemia. Hyperglycemia is a 
well known risk factor for diabetic 
retinopathy. However, there is no glycemic 
threshold for the development of long term 
complications in diabetic patients (Diabetes 
Control and Complications Trial, 1996). In 
diabetic IGF-II/LDLR–/–ApoB100/100 mice, the 
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plasma glucose levels were only moderately 
increased    simulating early diabetes treated 
with diet therapy in humans. However, the 
morphology of the retina was abundantly 
altered especially in the outer part already 
with the normal diet. Despite of this, there 
were no signs of microvascular damage. 
Hyperglycaemia causes the onset of diabetic 
retinopathy and the cascade of metabolic and 
biochemical changes long before disease 
pathology is detectable (Brownlee, 2001). In 
addition, hyperglycaemia is associated with 
biochemical alterations and apoptosis of 
neuronal and vascular cells in the retina 
(Gardner et al., 2002; Mizutani et al., 1996). 
Demonstrated by psychophysical and 
electrophysiological experiments, anomalies 
are developing especially in rod vision during 
the preclinical period of diabetic retinopathy 
although the fundus is normal. This is caused 
by changes in the circulation and slight 
reduction in oxygen supply in the retina 
(Arden, 2001). These findings are confirmed 
with diabetic cats, whose retinal oxygen 
tension is reduced when compared to control 
animals, even with no fluorescein 
angiographic evidence of actual capillary 
dropout (Linsenmeier et al., 1998). 
   In the retina, caspase-3 is activated in 
disorders that result in photoreceptor 
degeneration. Activation of caspase-3 has 
been noted in the rd-1 mouse, in the 
rhodopsin mutant rat, in chemically induced 
models of retinal degeneration, and in 
photoreceptor degeneration due to exposure 
to blue light (Jomary et al., 2001; Kim et al., 
2002; Liu et al., 1999; Wu et al., 2002; 
Yoshizawa et al., 2000). There is increasing 
evidence that diabetic patients with retinitis 
pigmentosa have a reduced risk of the 
development of preproliferative diabetic 
retinopathy (Arden, 2001; Arden et al., 
1998). It has been proposed that the loss of 
rods during retinitis pigmentosa leads to a net 
reduction in oxygen usage by the retina, a 
phenomenon that is intimately related to the 
high oxygen demands of these cells in 
combination with the dark adaptation 
response (Arden et al., 2005; Penn et al., 
2000). There is enhanced oxygen usage by 
rods under scotopic conditions, and, in some 
pathologies, this physiological phenomenon 
could serve to exacerbate pathologic hypoxia 
(Braun et al., 1995; Yu et al., 2000). Diabetic 
rho–/– mice have been shown to suffer less 
retinal hypoxia and reduced pathologic 
symptoms when compared with their diabetic 
controls with no retinal degeneration (de 
Gooyer et al., 2006). It has been suggested 
that photoreceptor metabolism could play a 
contributory role in the initiation and 
progression of diabetic retinopathy even 
before there is overt microvascular damage 
(Arden, 2001; Lahdenranta et al., 2001). It is 
also possible in our model, that the lack of 
microvascular diabetic retinopathy is due to 
excessive photoreceptor atrophy. 
6.5 Viral vectors 
The in vivo gene therapy approach in rodent 
models of ocular neovascularization has been 
shown to be efficient in multiple reports. 
Also the safety data of different viral vectors 
in larger animals is accumulating. 
Adenoviruses are relatively easy to produce, 
have a good capacity of 30 kb, and with an 
appropriate promoter can mediate good 
expression levels in many types of cells 
(Mori et al., 2002c). Baculoviruses cannot 
replicate in vertebrate cells and are also 
capable of transducing differentiated, 
nondividing cells (Hu, 2006; Mähönen et al., 
2007). In addition, they have a low 
cytotoxicity in mammalian cells even at a 
very high virus load and they can be easily 
produced in high titers (Airenne et al., 2003; 
Laitinen et al., 2005). Furthermore, the large 
size of the baculovirus makes it possible to 
simultaneously transfer more than one gene. 
AAVs are substantially more difficult to 
produce than Ad vectors and have limited 
capacity of less than 5 kb. Lentivirus vectors 
have a similar transgene capacity (8–10 kb) 
but they can easily be generated in high titres 
(Lever et al., 2004). The major disadvantage 
with adenoviral vectors is that they induce an 
immune response that leads to inflammation, 
and mediates the destruction of transduced 
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cells reducing transgene expression (Loewen 
et al., 2004). Baculovirus causes a similar 
inflammatory response in transduced eyes. 
Fortunately the anterior chamber, the 
subretinal space and to a lesser extent the 
vitreous cavity are sheltered from a full 
immunological response that limits the 
immune response against the vector. 
However, AAV and lentivirus appear to 
invoke minor immune response and therefore 
mediate prolonged transgene expression 
(Bennett, 2003).     
   Intravitreally administered adenoviruses 
transduce genes in the nerve fibre and the 
ganglion cell layers in the retina and also in 
the anterior segment of the eye. On the other 
hand, baculovirus-mediated intravitreal gene 
transfer had the highest efficiency in the 
photoreceptor layer and the RPE followed by 
the inner retina. Intravitreally administrated 
AAVs transduce ganglion cells, trabecular 
meshwork cells and various cells of the inner 
nuclear layer (Ali et al., 1998b; Borrás et al., 
2006; Grant et al., 1997; Martin et al., 2002; 
Surace and Auricchio, 2008).   Lentiviral 
intravitreal gene transfer does not cause 
transgene expression in the retina (Greenberg 
et al., 2007). In order to transduce deeper 
layers of the retina, adenoviruses, AAVs and 
lentiviruses should be administered 
subretinally, whereas baculoviruses are able 
to transduce genes to deeper layers of the 
retina even after intravitreal injection.      
   Although intravitreal injection is somewhat 
less efficient than subretinal injection 
particularly when gene delivery to the outer 
retina is concerned, there are clinical aspects 
which favour this technique. The subretinal 
space is small, hence the subretinal injection 
is technically more difficult and only a small 
volume can be injected. Retinal 
neovascularization for example in 
proliferative diabetic retinopathy arises from 
the retina extending into the vitreous gel, and 
is therefore easily accessed with intravitreal 
techniques.       
   Viral vectors are in general more efficient 
than non-viral vectors in delivering genetic 
material into cells in vivo, and about 70% of 
the clinical trials are performed using viral 
vectors (Gene Therapy Clinical Trials). 
However, their safety is a concern. To 
achieve extended duration of transgene 
expression for gene therapeutic applications, 
the transgene should be either integrated into 
the genome or administered repeatedly. 
Chromosomal integration poses the risk of 
insertional mutagenesis and repeated 
administration of viruses might provoke an 
immune response with serious or even fatal 
consequences (Thomas et al., 2003). Non-
viral vectors are safer than virus-mediated 
gene delivery, but far less efficient and 
shorter in their duration (Abdallah et al., 
1995; Herweijer and Wolff, 2003; Niidome 
and Huang, 2002). A limitation of this 
approach is that long-term therapeutic 
transgene expression has been difficult to 
achieve due to the inefficiency of delivery.  
6.6 Ocular gene therapy 
The eye is one of the most suitable targets for 
gene therapy. It is easily accessible and 
allows restricted application of therapeutic 
agents with limited risk of systemic effects 
with a single injection. In addition, the effects 
of the treatment may be monitored by a 
variety of non-invasive examinations such as 
ophthalmoscopy, ERG and OCT. The amount 
of virus injected into the retina is about 
1/1000 of the amount used for systemic 
diseases. A virus delivered to the eye is 
unlikely to cause any systemic disease 
(Bennett and Maguire, 2000). Gene transfer 
experiments have demonstrated that it is 
possible to deliver transgenes to the retina in 
vivo in stable and efficient fashion with 
minimal toxicity (Hauswirth and Beaufrere, 
2000). However, the optimal gene transfer 
vector is not developed yet. Permanent 
models of retinal and choroidal neovascular 
disorders in larger animals would simulate 
clinical conditions better than recently used 
transient models. Attachment of regulation 
elements or tissue-specific promoters into the 
vector construct would increase their 
efficiency and safety in gene therapy.  
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   Major steps have been taken forward in the 
treatment of inherited diseases in the eye. A 
large number of inherited ocular diseases 
have been defined at the molecular level; 
there are approximately 150 retinal disease 
loci with 90 disease-causing genes identified 
to date (Bainbridge et al., 2006). However, 
there are still many unsolved problems. 
Several diseases have complexed pathways 
which complicate the treatments. Phenotypes 
of retinal diseases vary from early and severe 
to late and progressive. Slowly progressive 
diseases have a much wider therapeutic 
window than more acute, aggressively 
progressing and those with an earlier onset. 
AMD and diabetic retinopathy are chronic 
diseases and because of that permanent 
expression of therapeutic genes is required. 
Also the therapy should occur early enough 
before the retina is permanently damaged.  
   Encouriging results in animal models have 
led to phase I clinical trials in patients with 
neovascular AMD. The improvement of gene 
therapy vectors has prolonged the expression 
period of the introduced gene after a single 
injection (Cao, 2001). Thus, gene therapy 
with angiogenesis inhibitors may be an 
option to repeated administrations that are 
costly and increase the risks of complications. 
Inhibition of CNV by gene therapy is also 
reached without delivery of vector 
intraocularly (Gehlbach et al., 2003a; Saishin 
et al., 2005).  
   In diabetic retinopathy, the complexicity of 
the disease offers several alternative targets 
for therapeutic intervention. In addition to 
targeting angiogenic factors, gene transfer of 
proteins targeted to aldose reductase, AGEs 
or PKC offers different options to influence 
the disease. RNA interference offers a 
potential approach for therapeutic gene 
silencing for downregulation of pathogenic 
proteins in acquired disorders (Campochiaro, 
2004; Reich et al., 2003). Also inhibition of 
inflammation involved in many ocular 
neovascular diseases offers an alternative 
treatment pathway. Recent success in clinical 
trials of gene therapy has demonstrated that 
gene-based therapies can be effective in 
patients (Bainbridge et al., 2008; Maguire et 
al., 2008). Although ocular neovascular 
disorders are not life threatening, we should 
not underestimate the impact of visual 
impairment on the quality of life. 
 
7 CONCLUSIONS 
 
Significant progress has been made in the 
understanding of molecular pathogenesis of 
several retinal neovascular disorders 
providing multiple new targets for therapeutic 
interventions. In this study, we evaluated 
which factors are involved in the 
pathogenesis of proliferative diabetic 
retinopathy and retinal neovascularization. 
Multiple factors, suitable as targets of 
therapeutic interventions are present in the 
neovascular tissues of proliferative diabetic 
retinopathy. There are also differences in the 
expression pattern of angiogenic factors 
between type 1 and type 2 diabetic 
retinopathy. These may partly explain the 
differences in their clinical course. In type 1 
diabetics, VEGF-A was much more abundant 
than the other growth factors but in type 2 
diabetics, VEGF-D was equally or more 
abundantly present than VEGF-A in the 
neovascular tufts in over 50% of cases. ANG-
2 seems to be an important factor in 
neovessel growth both in type 1 and type 2 
diabetics. These differencies should be 
considered when developing new treatment 
options for patients with proliferative diabetic 
retinopathy. In type 1 diabetics, the first 
targets should be VEGF-A, VEGFR-2 and 
ANG-2 while in type 2 diabetics, preventing 
the action of VEGF-D and other VEGFRs 
should also be considered.  
   Intravitreal overexpression of VEGF-A165 
led to the break down of the blood retina 
barrier, increased permeability and ultimately 
a dose-dependent neovessel formation in the 
rabbit eye. Blocking the action of VEGF-A165 
prevented the progression of the angiogenic 
process. Intravitreally administred VEGF-
D∆N∆C leads to similar breakdown of the 
blood retina barrier and dilatation of 
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capillaries as VEGF-A165 but it was not 
capable of neovessel formation alone. 
   Adenovirus and baculovirus vectors turned 
out to be efficient vectors for ocular gene 
transfer. However, both vectors initiated an 
immune response in the target tissue which 
limited the expression of the transducted gene 
to a few weeks. In this study, intravitreally 
injected adenovirus vector was particularly 
efficient in delivering agents to the ganglion 
cell layer and inner retina.  Baculoviruses 
showed transduction in the RPE and 
photoreceptor layer even after the intravitreal 
injection and could therefore offer a novel 
choice for the development of treatments for 
certain diseases, such as AMD.  
   Diabetic IGF-II/LDLR–/–ApoB100/100 mice 
showed abundant changes in retinal 
morphology with no signs of microvascular 
damage normally seen in diabetic retinopathy 
possibly due to excessive photoreceptor 
atrophy. This model might useful in studying 
early diabetic changes and changes related to 
oxidative stress including retinal 
degenerations. 
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